News Releases

 

This information is part of the archives and is no longer current and may no longer be accurate.

Date Title  
Sep 09, 2019 DURECT Earns $10 Million Milestone Payment for Further Development of a Long-Acting Injectable HIV Investigational Product Utilizing DURECT's SABER® Technology
CUPERTINO, Calif. , Sept. 9, 2019 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) announced today that further development of a long-acting injectable HIV investigational product utilizing DURECT's SABER ® technology has triggered a $10 million milestone payment from Gilead Sciences, Inc.
Sep 04, 2019 DURECT to Present at the 21st Annual Rodman and Renshaw Global Investment Conference Sponsored by H.C. Wainwright
CUPERTINO, Calif. , Sept. 4, 2019 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) announced today that James E. Brown , Chief Executive Officer will be presenting at the 21st Annual Global Rodman and Renshaw Investment Conference , sponsored by H. C.
Aug 01, 2019 DURECT Corporation Announces Second Quarter 2019 Financial Results and Update of Programs
Live Webcast of Earnings Call Today at 4:30 p.m. Eastern Time CUPERTINO, Calif. , Aug. 1, 2019 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended June 30, 2019 and provided a corporate update.
Jul 25, 2019 DURECT Corporation to Announce Second Quarter 2019 Financial Results on August 1
CUPERTINO, Calif. , July 25, 2019 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) today announced that it will report second quarter and six months ended June 30, 2019 financial results and host a conference call after the market close on Thursday, August 1, 2019 .
Jul 22, 2019 DURECT and Gilead Enter into License Agreement for Long-Acting Injectable HIV Investigational Product
Gilead Also Receives Exclusive Option to License Additional Products for HIV and Hepatitis B CUPERTINO, Calif. , July 22, 2019 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) announced today that it has entered into an agreement with Gilead Sciences, Inc.
Jul 17, 2019 DURECT Announces that the FDA Agreed to File the Full Response to the POSIMIR® Complete Response Letter as a Complete Class 2 Resubmission
User Fee Goal Date is December 27, 2019 CUPERTINO, Calif. , July 17, 2019 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) today announced that the U.S. Food and Drug Administration ( FDA ) has acknowledged that the submission of DURECT's full response to the Complete Response Letter (CRL) it
Jun 27, 2019 DURECT Announces Submission to FDA of a Full Response to the POSIMIR® Complete Response Letter
CUPERTINO, Calif. , June 27, 2019 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced it has submitted a full response to the Complete Response Letter (CRL) it previously received from U.S. Food and Drug Administration ( FDA ) related to POSIMIR ® (bupivacaine extended-release
Jun 25, 2019 DURECT Receives Approval from Nasdaq for Transfer of Listing to Nasdaq Capital Market
CUPERTINO, Calif. , June 25, 2019 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it received approval from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq") to transfer the listing of the Company's common stock from the Nasdaq Global Market to the
Jun 20, 2019 DURECT Announces $15 Million Registered Direct Offering
CUPERTINO, Calif. , June 20, 2019 /PRNewswire/ --  DURECT Corporation (" DURECT " or the "Company") (Nasdaq: DRRX) today announced that it has entered into a securities purchase agreement with certain investors pursuant to which, subject to the terms and conditions expressed therein, the Company
Jun 18, 2019 DURECT Announces Completion of the 90 mg Severe Cohort and Dose Escalation Committee Approval to Commence 150 mg Dosing in Patients with Severe Alcoholic Hepatitis (AH) in its Ongoing DUR-928 Phase 2a AH Trial
CUPERTINO, Calif. , June 18, 2019 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it has completed dosing the 90 mg cohort of severe AH patients in its ongoing DUR-928 Phase 2a clinical trial, and that after reviewing safety and pharmacokinetic (PK) data from the completed
May 16, 2019 DURECT to Present at the 20th Annual B. Riley FBR Institutional Investor Conference on May 22, 2019
CUPERTINO, Calif. , May 16, 2019 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) announced today that James E. Brown , Chief Executive Officer, and Michael H. Arenberg , Chief Financial Officer, will be participating in the 20 th Annual B. Riley FBR Institutional Investor Conference , taking
May 08, 2019 DURECT Corporation Announces Preliminary Data from the Ongoing DUR-928 Alcoholic Hepatitis Phase 2a Trial
Live  Webcast of AH Data Presentation and Discussions by KOLs Steven Flamm, M.D., Tarek  I. Hassanein, M.D. and Paul Kwo, M.D. Tomorrow, Wednesday, May 8, 2019 at 8:30  a.m. ET CUPERTINO, Calif., May 7, 2019 /PRNewswire/ --  DURECT Corporation  (Nasdaq: DRRX) today announced preliminary data from
May 07, 2019 DURECT Corporation Announces First Quarter 2019 Financial Results and Update of Programs
Live Webcast of Alcoholic Hepatitis KOL and Earnings Call on Wednesday, May 8th at 8:30 a.m. ET Call will feature discussions by KOLs Steven Flamm, M.D.. Tarek I. Hassanein, M.D., and Paul Kwo, M.D. CUPERTINO, Calif. , May 7, 2019 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) today announced
May 03, 2019 DURECT Corporation to Present Preliminary Data from the Ongoing DUR-928 Alcoholic Hepatitis Phase 2a Trial and Report First Quarter 2019 Financial Results
Call will feature discussions by KOLs Steven Flamm, M.D.. Tarek I. Hassanein, M.D., and Paul Kwo, M.D. Conference call and live webcast with slides on Wednesday, May 8th at 8:30 a.m. ET CUPERTINO, Calif. , May 3, 2019 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it will
Apr 25, 2019 DURECT Appoints Two New Board Members
CUPERTINO, Calif. , April 25, 2019 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) announced today the appointment of two new members to its board of directors.  Dr. Gail M. Farfel , Executive Vice President and Chief Development Officer of Zogenix, Inc. , and Judith J.
Apr 01, 2019 DURECT to Present at the H.C. Wainwright Global Life Sciences Conference and Host an Upcoming KOL call on NASH
CUPERTINO, Calif. , April 1, 2019 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that Michael Arenberg , Chief Financial Officer, will be presenting at the H.C. Wainwright Global Life Sciences Conference on Tuesday, April 9 at 10:50 a.m. BST / 05.50 a.m.
Mar 27, 2019 DURECT Announces Patient Enrollment in Phase 1b Clinical Trial of Oral DUR-928 in Patients with Non-Alcoholic Steatohepatitis (NASH)
CUPERTINO, Calif. , March 27, 2019 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced it has commenced patient enrollment in a Phase 1b trial with oral DUR-928 in patients with NASH.  DUR-928, the lead investigational product in the Company's Epigenetic Regulator Program, is an
Mar 21, 2019 DURECT Announces Patient Dosing in Phase 2a Proof-of-Concept Clinical Trial of Topical DUR-928 in Patients with Mild to Moderate Plaque Psoriasis
CUPERTINO, Calif. , March 21, 2019 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced it has commenced patient dosing in a Phase 2a proof-of-concept trial with topical DUR-928 in patients with mild to moderate plaque psoriasis.  DUR-928, the lead investigational product in the
Mar 07, 2019 DURECT Corporation Announces Fourth Quarter and Full Year 2018 Financial Results and Update of Programs
Advancing To Next Dosing Cohort in Severe Alcoholic Hepatitis (AH) Patients Live Webcast of Earnings Call Today at 4:30 p.m. Eastern Time CUPERTINO, Calif. , March 7, 2019 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months and year ended
Mar 04, 2019 DURECT Corporation Invites You to Join its Fourth Quarter 2018 Earnings Conference Call
CUPERTINO, Calif. , March 4, 2019 /PRNewswire/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) fourth quarter 2018 financial results press release, you are invited to listen to a conference call that will be broadcast live over the internet on Thursday, March 7, 2019 at 4:30 pm Eastern
Feb 27, 2019 DURECT Announces Plans to Submit to FDA a Full Response to the POSIMIR® Complete Response Letter
Live Webcast Today at 10:30 a.m. Eastern Time CUPERTINO, Calif. , Feb. 27, 2019 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) today announced it has completed a comprehensive review of its POSIMIR ® (bupivacaine extended-release solution) program and plans to submit a full response to the
Feb 21, 2019 DURECT Corporation to Participate in the Berenberg NASH Day
CUPERTINO, Calif. , Feb. 21, 2019 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) today announced that James E. Brown , President and CEO, and Mike Arenberg , Chief Financial Officer, will be participating in the Berenberg NASH Day, taking place Tuesday, February 26, 2019 , at Berenberg's New
Jan 07, 2019 DURECT Corporation Provides Corporate Update
Live Webcast Today at 8:00 a.m. Eastern Time CUPERTINO, Calif. , Jan. 7, 2019 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) has refined and focused its clinical development strategy for DUR-928, the lead product candidate in its Epigenetic Regulator Program, to prioritize indications with
Jan 03, 2019 DURECT Corporation Announces Investor Call to Provide Corporate Update
CUPERTINO, Calif. , Jan. 3, 2019 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) invites interested parties to listen to a corporate update conference call that will be broadcast live over the internet on Monday, January 7, 2019 at 8:00 am Eastern Time ( 5:00 am Pacific Time ).
Dec 19, 2018 Commercial Launch Plans Announced for PERSERIS™ (risperidone) Extended-Release Injectable Suspension for the Treatment of Schizophrenia in Adults
Indivior PLC Announces Plan for Commercial Launch in February 2019 with 50 Sales Representatives CUPERTINO, Calif. , Dec. 19, 2018 /PRNewswire/ --  DURECT Corporation  (Nasdaq: DRRX) today announced that Indivior PLC (LON: INDV) stated on December 18, 2018 that it is moving ahead with the launch of
Dec 17, 2018 DURECT Corporation Announces Retirement of Dr. Felix Theeuwes as Chairman of the Board and Distinguished Scientist
David Hoffmann, Current Lead Independent Director and Chairman of the Audit Committee, to Assume Position of Chairman of the Board CUPERTINO, Calif. , Dec. 17, 2018 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) announced today that Felix Theeuwes will retire as Chairman of the Board and
Nov 19, 2018 DURECT Announces Amendment to Accelerate Ongoing Phase 2a Trial of DUR-928 in Alcoholic Hepatitis (AH) by Allowing Dosing of Severe AH Patients in Parallel to Moderate AH Patients
CUPERTINO, Calif. , Nov. 19, 2018 /PRNewswire/ -- DURECT Corporation  (Nasdaq: DRRX) today announced it has amended its ongoing Phase 2a clinical trial of intravenously administered DUR-928 in patients with alcoholic hepatitis (AH) to accelerate the initiation of dosing of severe AH patents.  The
Nov 07, 2018 DURECT Corporation Announces Third Quarter 2018 Financial Results and Provides Corporate Update
Live Webcast of Earnings Call Today at 4:30 p.m. Eastern Time CUPERTINO, Calif. , Nov. 7, 2018 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended September 30, 2018 and provided a corporate update.
Nov 01, 2018 DURECT Corporation Invites You to Join its Third Quarter 2018 Earnings Conference Call
CUPERTINO, Calif. , Nov. 1, 2018 /PRNewswire/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) third quarter 2018 financial results press release, you are invited to listen to a conference call that will be broadcast live over the internet on Wednesday, November 7, 2018 at 4:30 pm Eastern
Oct 25, 2018 DURECT Announces Abstracts on DUR-928 to be Presented at Upcoming Scientific Meetings
ASN Kidney Week Meeting and American College of Toxicology's Annual Meeting CUPERTINO, Calif. , Oct. 25, 2018 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) announced today that two posters on DUR-928 will be presented at the ASN Kidney Week Meeting on Saturday, October 27 and one poster will
Oct 01, 2018 DURECT Corporation Appoints Michael H. Arenberg, J.D., M.B.A. as Chief Financial Officer
CUPERTINO, Calif. , Oct. 1, 2018 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today the appointment of Michael H. Arenberg to the position of Chief Financial Officer, effective October 15, 2018 . Mr. Arenberg will be responsible for overseeing all financial and capital market
Sep 25, 2018 DURECT to Present at the Cantor Fitzgerald Global Healthcare Conference
CUPERTINO, Calif. , Sept. 25, 2018 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) announced today that James E. Brown , President and CEO, will be presenting at the Cantor Fitzgerald Global Healthcare Conference on Wednesday, October 3 at 1:40 p.m.
Sep 18, 2018 DURECT Announces Methydur Sustained Release Capsules Receive Marketing Authorization for ADHD in Taiwan
- ORADUR®-Methylphenidate ER now called Methydur Sustained Release Capsules in Taiwan - Developed by Orient Pharma under a license to the ORADUR® technology from DURECT CUPERTINO, Calif. , Sept. 18, 2018 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) today announced that Orient Pharma Co., Ltd.
Aug 30, 2018 DURECT Announces Receipt of $5 Million Milestone Payment from Indivior
Milestone payment triggered by NDA approval of PERSERIS™ (risperidone) CUPERTINO, Calif. , Aug. 30, 2018 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it has received a $5 million milestone payment from Indivior PLC (LON: INDV), triggered by Indivior's approval of the New
Aug 27, 2018 DURECT to Present at the 20th Annual Rodman & Renshaw Global Investment Conference
CUPERTINO, Calif. , Aug. 27, 2018 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) announced today that James E. Brown , President and CEO, will be presenting at the 20 th Annual Rodman & Renshaw Global Investment Conference , sponsored by H.C. Wainwright & Co.
Aug 06, 2018 DURECT's Licensee Pain Therapeutics Receives Complete Response Letter from FDA for REMOXY® ER (oxycodone) Extended-Release Capsules CII
CUPERTINO, Calif. , Aug. 6, 2018 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that its licensee, Pain Therapeutics (Nasdaq: PTIE) reported that it received a Complete Response Letter from the U.S. Food and Drug Administration ( FDA ) for Pain Therapeutics' New Drug Application
Aug 01, 2018 DURECT Corporation Announces Second Quarter 2018 Financial Results and Provides Corporate Update
Live Webcast of Earnings Call Today at 4:30 p.m. Eastern Time CUPERTINO, Calif. , Aug. 1, 2018 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended June 30, 2018 and provided a corporate update.
Jul 30, 2018 DURECT Announces FDA Approval of Indivior's PERSERIS™ (risperidone) Extended-Release Injectable Suspension for the Treatment of Schizophrenia in Adults
Approval triggers $5 million milestone payment to DURECT and future earn-out payments based on U.S. net sales CUPERTINO, Calif. , July 30, 2018 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) today announced that Indivior PLC (LON: INDV) has reported that the U.S.
Jul 24, 2018 DURECT Corporation Invites You to Join its Second Quarter 2018 Earnings Conference Call
CUPERTINO, Calif. , July 24, 2018 /PRNewswire/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) second quarter 2018 financial results press release, you are invited to listen to a conference call that will be broadcast live over the internet on Wednesday, August 1, 2018 at 4:30 pm Eastern
Jun 27, 2018 Results of FDA Advisory Committee Meeting for REMOXY® ER
CUPERTINO, Calif. , June 26, 2018 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) today reported that a joint meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee of the U.S.
May 09, 2018 DURECT Announces Amendment to Licensing Agreement with Sandoz Related to POSIMIR® (SABER®-Bupivacaine)
CUPERTINO, Calif. , May 9, 2018 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) today announced it has entered into an amendment (the "Amendment") to the development and commercialization agreement with Sandoz AG , a division of Novartis (NYSE: NVS), regarding POSIMIR ® (SABER ® -bupivacaine) in
May 09, 2018 DURECT Announces Amendment to Licensing Agreement with Sandoz Related to POSIMIR® (SABER®-Bupivacaine)
CUPERTINO, Calif. , May 9, 2018 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) today announced it has entered into an amendment (the "Amendment") to the development and commercialization agreement with Sandoz AG , a division of Novartis (NYSE: NVS), regarding POSIMIR ® (SABER ® -bupivacaine) in
May 02, 2018 DURECT Corporation Announces First Quarter 2018 Financial Results and Provides Corporate Update
Live Webcast of Earnings Call Today at 4:30 p.m. Eastern Time CUPERTINO, Calif. , May 2, 2018 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended March 31, 2018 and provided a corporate update.
May 02, 2018 DURECT Corporation Announces First Quarter 2018 Financial Results and Provides Corporate Update
Live Webcast of Earnings Call Today at 4:30 p.m. Eastern Time CUPERTINO, Calif. , May 2, 2018 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended March 31, 2018 and provided a corporate update.
Apr 25, 2018 DURECT Announces Patient Dosing in Phase 2a Trial of DUR-928 in Alcoholic Hepatitis
CUPERTINO, Calif. , April 25, 2018 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced it has commenced patient dosing in a Phase 2a clinical trial of DUR-928 in patients with alcoholic hepatitis (AH).  DUR-928, the lead investigational product in our Epigenetic Regulator Program, is
Apr 25, 2018 DURECT Announces Patient Dosing in Phase 2a Trial of DUR-928 in Alcoholic Hepatitis
CUPERTINO, Calif. , April 25, 2018 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced it has commenced patient dosing in a Phase 2a clinical trial of DUR-928 in patients with alcoholic hepatitis (AH).  DUR-928, the lead investigational product in our Epigenetic Regulator Program, is
Apr 24, 2018 DURECT Corporation Invites You to Join its First Quarter 2018 Earnings Conference Call
CUPERTINO, Calif. , April 24, 2018 /PRNewswire/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) first quarter 2018 financial results press release, you are invited to listen to a conference call that will be broadcast live over the internet on Wednesday, May 2, 2018 at 4:30 pm Eastern
Apr 24, 2018 DURECT Corporation Invites You to Join its First Quarter 2018 Earnings Conference Call
CUPERTINO, Calif. , April 24, 2018 /PRNewswire/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) first quarter 2018 financial results press release, you are invited to listen to a conference call that will be broadcast live over the internet on Wednesday, May 2, 2018 at 4:30 pm Eastern
Mar 29, 2018 DURECT Corporation to Host Key Opinion Leader Call on Alcoholic Hepatitis
CUPERTINO, Calif. , March 29, 2018 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) today announced it will host a key opinion leader (KOL) call on the treatment of alcoholic hepatitis (AH) on Thursday, April 5 at 11:00 a.m. Eastern Time . The call will feature a presentation by KOL Paul Kwo, MD,
Mar 20, 2018 DURECT Announces FDA Advisory Committee Meeting for REMOXY® ER
CUPERTINO, Calif. , March 20, 2018 /PRNewswire/ --   DURECT Corporation (Nasdaq: DRRX) today announced that its licensee, Pain Therapeutics (Nasdaq: PTIE), reported yesterday that the U.S. Food and Drug Administration ( FDA ) will hold an Advisory Committee Meeting to discuss the New Drug
Mar 01, 2018 DURECT Corporation Announces Fourth Quarter and Full Year 2017 Financial Results and Update of Programs
Live Webcast of Earnings Call Today at 4:30 p.m. Eastern Time CUPERTINO, Calif. , March 1, 2018 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months and year ended December 31, 2017 and provided a corporate update.
Feb 26, 2018 DURECT Announces Patient Dosing in Phase 2a Trial of DUR-928 in Primary Sclerosing Cholangitis (PSC)
CUPERTINO, Calif. , Feb. 26, 2018 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) today announced it has commenced patient dosing in a Phase 2a clinical trial of DUR-928 in patients with primary sclerosing cholangitis (PSC).  DUR-928, the lead investigational product in our Epigenetic Regulator
Feb 22, 2018 DURECT Corporation Invites You to Join its Fourth Quarter 2017 Earnings Conference Call
CUPERTINO, Calif. , Feb. 22, 2018 /PRNewswire/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) fourth quarter 2017 financial results press release, you are invited to listen to a conference call that will be broadcast live over the internet on Thursday, March 1, 2018 at 4:30 pm Eastern
Feb 20, 2018 DURECT Corporation to Host Key Opinion Leader Call on Treatment of Primary Sclerosing Cholangitis (PSC)
CUPERTINO, Calif. , Feb. 20, 2018 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) today announced it will host a key opinion leader (KOL) call on the treatment of primary sclerosing cholangitis (PSC) on Monday, February 26 at 12:00 p.m. Eastern Time .
Feb 14, 2018 DURECT Announces Resubmission of REMOXY® ER New Drug Application by its licensee, Pain Therapeutics
CUPERTINO, Calif. , Feb. 14, 2018 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that its licensee, Pain Therapeutics (Nasdaq: PTIE), reported yesterday that it has resubmitted the New Drug Application (NDA) for REMOXY ® ER to the U.S.
Dec 13, 2017 DURECT Announces NDA Acceptance of Indivior's RBP-7000 Risperidone Monthly Depot
CUPERTINO, Calif. , Dec. 13, 2017 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) today announced that Indivior PLC (LON: INDV) has reported that the U.S. Food and Drug Administration ( FDA ) has accepted the New Drug Application (NDA) for RBP-7000.  RBP-7000 is an investigational, once-monthly
Nov 01, 2017 DURECT Corporation Announces Third Quarter 2017 Financial Results and Provides Corporate Update
Live Webcast of Earnings Call Today at 4:30 p.m. Eastern Time CUPERTINO, Calif. , Nov. 1, 2017 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended September 30, 2017 and provided a corporate update.
Oct 26, 2017 DURECT Corporation Invites You to Join its Third Quarter 2017 Earnings Conference Call
CUPERTINO, Calif. , Oct. 26, 2017 /PRNewswire/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) third quarter 2017 financial results press release, you are invited to listen to a conference call that will be broadcast live over the internet on Wednesday, November 1, 2017 at 4:30 pm
Oct 19, 2017 DURECT Announces Top-line Results from the PERSIST Phase 3 Trial of POSIMIR® (SABER®-Bupivacaine) Did Not Meet Primary Efficacy Endpoint
CUPERTINO, Calif. , Oct. 19, 2017 /PRNewswire/ --   DURECT Corporation (Nasdaq: DRRX) today reported that PERSIST, the Phase 3 clinical trial for POSIMIR ® (SABER ® -Bupivacaine), did not meet its primary efficacy endpoint of reduction in pain on movement over the first 48 hours after surgery as
Oct 02, 2017 DURECT and Indivior PLC Sign a $17.5 Million Patent Purchase Agreement
Agreement Relates to Intellectual Property for RBP-7000, Indivior's Investigational Once-Monthly Injectable Risperidone Product for Schizophrenia CUPERTINO, Calif. , Oct. 2, 2017 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) today announced a patent purchase agreement with Indivior UK Limited
Sep 20, 2017 DURECT Appoints Dr. Myriam Theeuwes as Senior Vice President, Clinical Development
CUPERTINO, Calif. , Sept. 20, 2017 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that Dr. Myriam Theeuwes has joined DURECT as Senior Vice President, Clinical Development.  Dr. Theeuwes joins DURECT from Johnson & Johnson where she spent 18 years, most recently as Compound
Sep 05, 2017 DURECT to Participate in Upcoming Healthcare Conferences
CUPERTINO, Calif. , Sept. 5, 2017 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that management is scheduled to present at two upcoming investment conferences.  James E. Brown , President and CEO, will present at the Rodman & Renshaw Global Investment Conference on Tuesday,
Aug 08, 2017 DURECT Corporation Announces Second Quarter 2017 Financial Results and Provides Corporate Update
Live Webcast of Earnings Call Today at 4:30 p.m. Eastern Time CUPERTINO, Calif. , Aug. 8, 2017 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended June 30, 2017 and provided a corporate update.   Executed a U.S.
Aug 08, 2017 ORADUR®-Methylphenidate ER Capsule Achieves Primary Endpoint in Phase 3 Study in ADHD in Taiwan
- Statistically significant difference between ORADUR-Methylphenidate ER Capsule and placebo on SNAP-IV teacher form score - Study drug was generally safe and well tolerated CUPERTINO, Calif. , Aug. 8, 2017 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that Orient Pharma Co.,
Aug 01, 2017 DURECT Corporation Invites You to Join its Second Quarter 2017 Earnings Conference Call
CUPERTINO, Calif. , Aug. 1, 2017 /PRNewswire/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) second quarter 2017 financial results press release, you are invited to listen to a conference call that will be broadcast live over the internet on Tuesday, August 8, 2017 at 4:30 pm Eastern
Jun 22, 2017 DURECT Completes Enrollment in PERSIST, Phase 3 trial for POSIMIR®
Top-Line Data on Track for Q4 2017 CUPERTINO, Calif. , June 22, 2017 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that patient enrollment has been completed in PERSIST, the pivotal Phase 3 clinical trial of POSIMIR® (SABER®-Bupivacaine), an investigational locally acting,
Jun 19, 2017 DURECT's Collaboration with Sandoz Clears HSR Review and is Effective
C UPERTINO , C alif., June 19, 2017 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that the previously disclosed development and commercialization agreement with Sandoz AG , a division of Novartis (NYSE: NVS) , to develop and market in the United States DURECT's POSIMIR ® (SABER
May 10, 2017 DURECT Corporation Announces First Quarter 2017 Financial Results and Provides Corporate Update
Live Webcast of Earnings Call Today at 4:30 p.m. Eastern Time CUPERTINO, Calif. , May 10, 2017 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended March 31, 2017 and provided a corporate update.   Total revenues were $4.6 million and net
May 08, 2017 DURECT and Sandoz have Signed a $293 Million Development and Commercialization Agreement for POSIMIR® (SABER®-Bupivacaine) Covering the United States
CUPERTINO, Calif. , May 8, 2017 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced a development and commercialization agreement with Sandoz AG , a division of Novartis (NYSE: NVS), to develop and market in the United States DURECT's POSIMIR ® (SABER ® -Bupivacaine), an
May 04, 2017 DURECT Corporation Invites You to Join its First Quarter 2017 Earnings Conference Call
CUPERTINO, Calif. , May 4, 2017 /PRNewswire/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) first quarter 2017 financial results press release, you are invited to listen to a conference call that will be broadcast live over the internet on Wednesday, May 10, 2017 at 4:30 pm Eastern Time
Apr 24, 2017 DURECT Announces Presentation of Data from a Phase 1b Study of DUR-928 in Nonalcoholic Steatohepatitis (NASH) at The International Liver Congress™ 2017
Biomarker analysis provides evidence for a potential therapeutic effect of DUR-928 in NASH CUPERTINO, Calif. , April 24, 2017 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company actively developing new therapeutics based on its Epigenetic Regulator Program and proprietary
Apr 17, 2017 DURECT to Present Clinical Data at the International Liver Congress™ 2017
EASL poster will feature data from a Phase 1b study of DUR-928 in nonalcoholic steatohepatitis (NASH) CUPERTINO, Calif. , April 17, 2017 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company actively developing new therapeutics based on its Epigenetic Regulator Program and
Apr 03, 2017 DURECT to Present at the H.C. Wainwright NASH Investor Conference
CUPERTINO, Calif. , April 3, 2017 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) announced today that Jim Brown , President and Chief Executive Officer, will be presenting at the H.C. Wainwright NASH Investor Conference on Monday, April 3  at 4:40 p.m.
Mar 14, 2017 DURECT Corporation Announces Fourth Quarter and Full Year 2016 Financial Results and Update of Programs
Live Webcast of Earnings Call Today at 4:30 p.m. Eastern Time CUPERTINO, Calif. , March 14, 2017 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months and year ended December 31, 2016 and provided a corporate update.
Feb 24, 2017 DURECT Corporation Invites You to Join its Fourth Quarter 2016 Earnings Conference Call
CUPERTINO, Calif. , Feb. 24, 2017 /PRNewswire/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) fourth quarter 2016 financial results press release, you are invited to listen to a conference call that will be broadcast live over the internet on Tuesday, March 14, 2017 at 4:30 pm Eastern
Jan 30, 2017 DURECT Corporation Announces Update on DUR-928 Development Program
CUPERTINO, Calif. , Jan. 30, 2017 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today provided an update on the DUR-928 development program.  DUR-928, our Epigenetic Regulator Program's lead product candidate, is an endogenous, small molecule, new chemical entity (NCE), which may have broad
Oct 31, 2016 DURECT Corporation Announces Third Quarter 2016 Financial Results and Update of Programs
CUPERTINO, Calif. , Oct. 31, 2016 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the third quarter of 2016.  Total revenues were $3.7 million and net loss was $8.8 million for the three months ended September 30, 2016 as compared to total revenues of $4.7
Oct 31, 2016 DURECT Corporation Announces Update on DUR-928 Development Program
Initial data from Phase 1b study in NASH CUPERTINO, Calif. , Oct. 31, 2016 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today provided an update on the DUR-928 development program including a description of data from the first cohort of a Phase 1b study with DUR-928 in patients with
Oct 21, 2016 DURECT Corporation Invites You to Join its Third Quarter 2016 Earnings Conference Call
CUPERTINO, Calif. , Oct. 21, 2016 /PRNewswire/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) third quarter 2016 financial results press release, you are invited to listen to a conference call that will be broadcast live over the internet on Monday, October 31, 2016 at 4:30 pm Eastern
Sep 26, 2016 DURECT's Licensee Pain Therapeutics Receives Complete Response Letter from FDA for REMOXY® ER (oxycodone) Extended-Release Capsules CII
CUPERTINO, Calif. , Sept. 26, 2016 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) today announced that its licensee, Pain Therapeutics (Nasdaq: PTIE) has received a Complete Response Letter from the U.S. Food and Drug Administration ( FDA ) for Pain Therapeutics' New Drug Application (NDA) for
Sep 06, 2016 DURECT to Present at the Rodman & Renshaw Global Investment Conference
CUPERTINO, Calif. , Sept. 6, 2016 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that Matt Hogan , Chief Financial Officer, will be presenting at the Rodman & Renshaw Global Investment Conference on Monday, September 12 at 9:35 a.m.
Aug 01, 2016 DURECT Corporation Announces Second Quarter 2016 Financial Results and Update of Programs
CUPERTINO, Calif. , Aug. 1, 2016 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) announced today financial results for the second quarter of 2016. Total revenues were $3.2 million and net loss was $9.0 million for the three months ended June 30, 2016 as compared to total revenues of $4.4 million
Jul 25, 2016 DURECT Corporation Invites You to Join its Second Quarter 2016 Earnings Conference Call
CUPERTINO, Calif. , July 25, 2016 /PRNewswire/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) second quarter 2016 financial results press release, you are invited to listen to a conference call that will be broadcast live over the internet on Monday, August 1, 2016 at 4:30 pm Eastern
Jul 01, 2016 DURECT Provides REMOXY® Update
Pain Therapeutics Announced today that an FDA Advisory Committee Meeting for REMOXY® is Not Needed and No Change to September 25, 2016 PDUFA Date CUPERTINO, Calif. , July 1, 2016 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that its licensee, Pain Therapeutics (Nasdaq: PTIE)
Jun 28, 2016 DURECT to Present at the Cantor Fitzgerald Healthcare Conference
CUPERTINO, Calif. , June 28, 2016 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) announced today that James E. Brown , President and CEO, will be presenting at the Cantor Fitzgerald Healthcare Conference on Tuesday, July 12 at 8:00 a.m. Eastern Time .  The conference is being held at Le Parker
May 31, 2016 DURECT to Present at the Jefferies Healthcare Conference
CUPERTINO, Calif. , May 31, 2016 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) announced today that Jim Brown , President and Chief Executive Officer, will be presenting at the Jefferies Healthcare Conference on Friday, June 10 at 1:30 pm Eastern Time . The conference is being held at the
May 19, 2016 DURECT Announces FDA Advisory Committee Meeting for REMOXY®
FDA's Tentative Date for Advisory Committee Meeting is August 5, 2016 and No Change to PDUFA Date of September 25, 2016 CUPERTINO, Calif. , May 19, 2016 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that its licensee, Pain Therapeutics (Nasdaq: PTIE) has announced that an
May 11, 2016 DURECT Announces New REMOXY® Data being Presented at American Pain Society Meeting
CUPERTINO, Calif. , May 11, 2016 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced researchers will present new data around REMOXY ' s abuse-deterrent properties at the 35 th Annual Scientific Meeting of the American Pain Society (APS) meeting.  The scientific poster is titled
May 05, 2016 DURECT Corporation Announces First Quarter 2016 Financial Results and Update of Programs
CUPERTINO, Calif. , May 5, 2016 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the first quarter of 2016.  Total revenues were $3.6 million and net loss was $7.9 million for the three months ended March 31, 2016 as compared to total revenues of $4.8 million
Apr 29, 2016 DURECT Announces Closing of Public Offering of Common Stock
CUPERTINO, Calif. , April 29, 2016 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced the closing of an underwritten public offering of 13,800,000 shares of its common stock, offered at a price of $1.25 per share to the public, including 1,800,000 shares purchased by the underwriters
Apr 28, 2016 DURECT Corporation Invites You to Join its First Quarter 2016 Earnings Conference Call
CUPERTINO, Calif. , April 28, 2016 /PRNewswire/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) first quarter 2016 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Thursday, May 5, 2016 at 4:30 pm Eastern
Apr 26, 2016 DURECT Announces Pricing of Public Offering of Common Stock
CUPERTINO, Calif. , April 26, 2016 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced the pricing of an underwritten public offering of 12,000,000 shares of its common stock, offered at a price of $1.25 per share to the public.  The gross proceeds to DURECT from this offering are
Apr 25, 2016 DURECT Announces Proposed Public Offering of Common Stock
CUPERTINO, Calif. , April 25, 2016 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) today announced that it is offering, subject to market conditions, shares of its common stock in an underwritten public offering. DURECT anticipates using the net proceeds from this offering for general corporate
Apr 12, 2016 DURECT Announces FDA Acceptance of REMOXY® NDA, PDUFA Date of September 25, 2016
CUPERTINO, Calif. , April 12, 2016 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) today announced its licensee, Pain Therapeutics (Nasdaq: PTIE), has been informed by the U.S. Food and Drug Administration ( FDA ) that the New Drug Application (NDA) for REMOXY ® , an abuse-deterrent formulation
Apr 07, 2016 DURECT Announces POSIMIR® Program Update
CUPERTINO, Calif. , April 7, 2016 /PRNewswire / -- DURECT Corporation (Nasdaq: DRRX) today announced that after the PERSIST Phase 3 trial for POSIMIR ® was underway and enrolling patients at multiple sites, the Company received a letter from FDA advising the Company to make a number of amendments
Mar 29, 2016 DURECT Announces Resubmission of REMOXY® New Drug Application to the U.S. Food and Drug Administration
CUPERTINO, Calif. , March 29, 2016 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced its licensee, Pain Therapeutics (Nasdaq: PTIE), has resubmitted the New Drug Application (NDA) for REMOXY ® (oxycodone capsules CII) to the U.S. Food and Drug Administration (FDA).   Pain
Feb 29, 2016 DURECT Corporation Announces Fourth Quarter 2015 Financial Results and Update of Programs
CUPERTINO, Calif. , Feb. 29, 2016 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended December 31, 2015 . Total revenues were $5.2 million for the three months ended December 31, 2015 and $4.3 million for the three months ended December 31
Feb 18, 2016 DURECT Corporation Invites You to Join its Fourth Quarter 2015 Earnings Conference Call
CUPERTINO, Calif. , Feb. 18, 2016 /PRNewswire/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) fourth quarter 2015 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Monday, February 29, 2016 at 4:30 pm
Jan 28, 2016 DURECT to Present at the BIO CEO & Investor Conference
CUPERTINO, Calif. , Jan. 28, 2016 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) announced today that Matt Hogan (Chief Financial Officer) will be presenting at the BIO CEO & Investor Conference on Monday, February 8 at 4:00 p.m. Eastern Time .  The conference is being held at the
Jan 11, 2016 DURECT Announces Initiation of DUR-928 Dosing in Patients
Single-Ascending-Dose Study in NASH Patients CUPERTINO, Calif. , Jan. 11, 2016 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced it has initiated a single-ascending-dose Phase 1b clinical trial with DUR-928 in patients with nonalcoholic steatohepatitis (NASH).  DUR-928 is an
Jan 06, 2016 DURECT Announces Positive Phase 1 Data for DUR-928
Initial Phase 1 Safety Studies Successfully Completed, Positioning for the Start of Patient Studies in 2016 CUPERTINO, Calif. , Jan. 6, 2016 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) today announced the successful completion of a Phase 1 clinical trial with an injectable formulation of
Nov 30, 2015 DURECT to Present at the Oppenheimer Healthcare Conference
CUPERTINO, Calif. , Nov. 30, 2015 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) announced today that Matt Hogan , Chief Financial Officer, will be presenting at the Oppenheimer Healthcare Conference on Tuesday, December 8 at 2:45 pm Eastern Time .  The conference is being held at the Westin
Nov 05, 2015 DURECT to Present at the Stifel Nicolaus Healthcare Conference
CUPERTINO, Calif. , Nov. 5, 2015 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that Jim Brown , President and Chief Executive Officer, will be presenting at the Stifel Nicolaus Healthcare Conference on Wednesday, November 18 at 9:30 am Eastern Time . The conference is being held
Nov 02, 2015 DURECT Corporation Announces Third Quarter 2015 Financial Results and Update of Programs
CUPERTINO, Calif. , Nov. 2, 2015 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the third quarter of 2015.  Total revenues were $4.7 million and net loss was $6.5 million for the three months ended September 30, 2015 as compared to total revenues of $4.3
Oct 26, 2015 DURECT Corporation Invites You to Join its Third Quarter 2015 Earnings Conference Call
CUPERTINO, Calif. , Oct. 26, 2015 /PRNewswire/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) third quarter 2015 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Monday, November 2, 2015 at 4:30 pm Eastern
Oct 15, 2015 DURECT to Present at the BIO Investor Forum
CUPERTINO, Calif. , Oct. 15, 2015 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) announced today that Matt Hogan , Chief Financial Officer, will be presenting at the BIO Investor Forum on Wednesday, October 21 at 9:30 a.m. Pacific time .  The conference is being held at the Parc55 Hotel in San
Aug 27, 2015 DURECT to Participate in Upcoming Healthcare Conferences
CUPERTINO, Calif. , Aug. 27, 2015 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that management is scheduled to present at three upcoming healthcare conferences.  James E. Brown , President and CEO, will present at the Rodman & Renshaw Investment Conference on Thursday,
Aug 03, 2015 DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs
CUPERTINO, Calif. , Aug. 3, 2015 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) announced today financial results for the second quarter of 2015.  Total revenues were $4.4 million and net loss was $5.5 million for the three months ended June 30, 2015 as compared to total revenues of $4.6
Jul 24, 2015 DURECT Corporation Invites You to Join its Second Quarter 2015 Earnings Conference Call
CUPERTINO, Calif. , July 24, 2015 /PRNewswire/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) second quarter 2015 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Monday, August 3, 2015 at 4:30 pm Eastern
Jun 29, 2015 DURECT to Present at the Cantor Fitzgerald Healthcare Conference
CUPERTINO, Calif. , June 29, 2015 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that James E. Brown , President and CEO, will be presenting at the Cantor Fitzgerald Healthcare Conference on Wednesday, July 8 at 11:45 a.m. Eastern Time .  The conference is being held at Le Parker
Jun 23, 2015 DURECT Announces Plans for a New POSIDUR™ (SABER®-Bupivacaine) Clinical Trial
CUPERTINO, Calif. , June 23, 2015 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) announced that, based on feedback from the FDA , it plans to conduct a new POSIDUR ™ (SABER ® -Bupivacaine) Phase 3 clinical trial consisting of approximately 300 patients undergoing laparoscopic cholecystectomy
May 18, 2015 DURECT Announces Positive Results from DUR-928 Multi-Dose Phase 1 Study
CUPERTINO, Calif. , May 18, 2015 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it has obtained positive results from a multi-dose Phase 1 clinical trial with an oral formulation of DUR-928, the lead molecule in DURECT's Epigenomic Regulator Program. DUR-928 is an
Apr 30, 2015 DURECT Corporation Announces First Quarter 2015 Financial Results and Update of Programs
CUPERTINO, Calif. , April 30, 2015 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) announced today financial results for the first quarter of 2015.  Total revenues were $4.8 million and net loss was $4.9 million for the three months ended March 31, 2015 as compared to total revenues of $6.3
Apr 22, 2015 DURECT Corporation Invites You to Join its First Quarter 2015 Earnings Conference Call
CUPERTINO, Calif. , April 22, 2015 /PRNewswire/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) first quarter 2015 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Thursday, April 30, 2015 at 4:30 pm
Mar 30, 2015 DURECT Announces Initiation of DUR-928 Multi-Dose Phase 1 Study
CUPERTINO, Calif. , March 30, 2015 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it has initiated a multi-dose Phase 1 clinical trial of an oral formulation of DUR-928, the lead molecule in DURECT's Epigenomic Regulator Program.  DUR-928 is an endogenous, small-molecule,
Mar 02, 2015 DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs
CUPERTINO, Calif. , March 2, 2015 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended December 31, 2014 . Total revenues were $4.3 million for the three months ended December 31, 2014 and for the three months ended December 31 , 2013.  Net
Mar 02, 2015 DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development
Initial Phase 1 Safety Study Successfully Completed, Building on Promising Body of Preclinical Data CUPERTINO, Calif. , March 2, 2015 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) today announced its Epigenomic Regulator Program, and the successful completion of a Phase 1 clinical trial with
Feb 23, 2015 DURECT Corporation Invites You to Join its Fourth Quarter 2014 Earnings Conference Call
CUPERTINO, Calif. , Feb. 23, 2015 /PRNewswire/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) fourth quarter 2014 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Monday, March 2, 2015 at 4:30 pm Eastern
Jan 29, 2015 DURECT to Present at the BIO CEO & Investor Conference
CUPERTINO, Calif. , Jan. 29, 2015 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that Matt Hogan (Chief Financial Officer) will be presenting at the BIO CEO & Investor Conference on Tuesday, February 10 at 8:00 a.m. Eastern Time .  The conference is being held at the
Dec 16, 2014 DURECT Enters into License Agreement Granting Santen the Worldwide Rights to a Sustained Release SABER® Ophthalmology Product
CUPERTINO, Calif. , Dec. 16, 2014 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) announced today that it has entered into an agreement with Santen Pharmaceutical Co., Ltd. granting Santen the exclusive worldwide rights to develop and commercialize a sustained release product utilizing DURECT's
Dec 01, 2014 DURECT to Present at the Oppenheimer Healthcare Conference
CUPERTINO, Calif. , Dec. 1, 2014 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) announced today that Matt Hogan , Chief Financial Officer, will be presenting at the Oppenheimer 25 th Annual Healthcare Conference on Wednesday, December 10 at 3:55 p.m.
Nov 11, 2014 DURECT Provides Update on POSIDUR™ Program
CUPERTINO, Calif. , Nov. 11, 2014 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) announced that it has received meeting minutes from its face-to-face meeting with the FDA on September 23, 2014 regarding the POSIDUR ™ program.   In the February 2014 Complete Response Letter (CRL), FDA indicated
Nov 03, 2014 DURECT Corporation Announces Third Quarter 2014 Financial Results and Update of Programs
CUPERTINO, Calif. , Nov. 3, 2014 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the third quarter of 2014.  Total revenues were $4.3 million and net loss was $7.1 million for the three months ended September 30, 2014 ,  compared to total revenues of $3.0
Oct 27, 2014 DURECT Provides Update on REMOXY® and POSIDUR™ Programs
CUPERTINO, Calif. , Oct. 27, 2014 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) reported today that Pfizer Inc. (NYSE: PFE) announced today that it has notified Pain Therapeutics, Inc. (Nasdaq: PTIE) that Pfizer has decided to discontinue its agreement to develop and commercialize  REMOXY ®
Oct 24, 2014 DURECT Corporation Invites You to Join its Third Quarter 2014 Earnings Conference Call
CUPERTINO, Calif. , Oct. 24, 2014 /PRNewswire/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) third quarter 2014 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Monday, November 3, 2014 at 4:30 pm Eastern
Oct 10, 2014 DURECT Announces POSIDUR™ (SABER®-Bupivacaine) Data Presentation at the American Society of Anesthesiologists Annual Meeting
CUPERTINO, Calif. , Oct. 10, 2014 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that data for POSIDUR ™ (SABER ® -Bupivacaine), an investigational drug for administration into the surgical site to produce post-surgical analgesia, is being presented at ANESTHESIOLOGY ™ 2014, the
Aug 25, 2014 DURECT to Present at the Rodman & Renshaw Investment Conference
CUPERTINO, Calif. , Aug. 25, 2014 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) announced today that James E. Brown , President and CEO, will be presenting at the Rodman & Renshaw Investment Conference on Wednesday, September 10  at 10:25 a.m.
Aug 07, 2014 DURECT Corporation Announces Second Quarter 2014 Financial Results and Update of Programs
CUPERTINO, Calif. , Aug. 7, 2014 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) announced today financial results for the second quarter of 2014.  Total revenues were $4.6 million and net loss was $5.5 million for the three months ended June 30, 2014 as compared to total revenues of $3.9
Jul 30, 2014 DURECT Corporation Invites You to Join its Second Quarter 2014 Earnings Conference Call
CUPERTINO, Calif. , July 30, 2014 /PRNewswire/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) second quarter 2014 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Thursday, August 7, 2014 at 4:30 pm
Jun 26, 2014 DURECT Secures $20 Million Debt Financing
CUPERTINO, Calif. , June 26, 2014 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it had entered into a Loan and Security Agreement (the "Loan Agreement") with Oxford Finance LLC , pursuant to which Oxford agreed to make a term loan to the Company in the principal amount of
Jun 09, 2014 DURECT to Present at The Wall Street Analyst Forum Institutional Investor Conference
CUPERTINO, Calif. , June 9, 2014 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that Matt Hogan , Chief Financial Officer, will be presenting at The 25 th Annual Wall Street Analyst Forum Institutional Investor Conference on Thursday, June 19 at 10:35 a.m.
May 16, 2014 DURECT Announces POSIDUR™ (SABER®-Bupivacaine) Data Presentation at the International Anesthesia Research Society (IARS) Annual Meeting
CUPERTINO, CA, May 16, 2014 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) today announced that data for POSIDUR™ (SABER®-Bupivacaine), an investigational drug for administration into the surgical site to produce post-surgical analgesia, is being presented at the International
May 07, 2014 DURECT Announces Participation in Bay Area Prescription Drug Abuse Summit Meeting
CUPERTINO, Calif. , May 7, 2014 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) today announced that James E. Brown , President and CEO of DURECT Corporation , will be an industry speaker at the Bay Area Prescription Drug Abuse Summit on May 7, 2014 in San Francisco.  The summit is an effort to
May 01, 2014 DURECT Corporation Announces First Quarter 2014 Financial Results and Update of Programs
CUPERTINO, Calif. , May 1, 2014 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the first quarter of 2014.  Total revenues were $6.3 million and net loss was $3.6 million for the three months ended March 31, 2014 as compared to total revenues of $4.2 million
Apr 23, 2014 DURECT Corporation Invites You to Join its First Quarter 2014 Earnings Conference Call
CUPERTINO, Calif. , April 23, 2014 /PRNewswire/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) first quarter 2014 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Thursday, May 1, 2014 at 4:30 pm Eastern
Apr 01, 2014 DURECT Announces POSIDUR™ (SABER®-Bupivacaine) Data Presentations at the 39th Annual American Society of Regional Anesthetic and Pain Medicine Meeting
CUPERTINO, Calif. , April 1, 2014 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) today announced that data for POSIDUR ™ (SABER ® -Bupivacaine), an investigational drug for administration into the surgical site to produce post-surgical analgesia, is being presented at the 39 th Annual American
Feb 27, 2014 DURECT Corporation Announces Fourth Quarter 2013 Financial Results and Update of Programs
CUPERTINO, Calif. , Feb. 27, 2014 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended December 31, 2013 . Total revenues were $4.3 million for the three months ended December 31, 2013 as compared to $3.3 million for the three months ended
Feb 18, 2014 DURECT Corporation Invites You to Join its Fourth Quarter 2013 Earnings Conference Call and Upcoming Investor Conference
CUPERTINO, Calif., Feb. 18, 2014 /PRNewswire/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) fourth quarter 2014 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Thursday, February 27, 2014 at 4:30 pm
Feb 12, 2014 DURECT Receives Complete Response Letter from FDA for POSIDUR™ (SABER®-Bupivacaine)
Company will Host Conference Call on February 13, 2014 CUPERTINO, Calif. , Feb. 12, 2014 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that the U.S. Food and Drug Administration ( FDA ) has issued a Complete Response Letter for POSIDUR ™ (SABER ® -Bupivacaine), an
Jan 07, 2014 Impax and DURECT Sign a $63 Million Agreement to Develop and Commercialize DURECT’s ELADUR® Pain Patch
HAYWARD, CA and CUPERTINO, CA, January 7, 2014 -- Impax Laboratories, Inc.(NASDAQ: IPXL) and DURECT Corporation (Nasdaq: DRRX) announced today that they have entered into an agreement granting Impax the exclusive worldwide rights to develop and commercialize ELADUR®, DURECT’s investigational
Nov 13, 2013 DURECT Announces Closing of Public Offering of Common Stock
CUPERTINO, Calif. , Nov. 13, 2013 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced the closing of an underwritten public offering of 7,142,858 shares of its common stock, offered at a price of $1.40 per share to the public.  All of the shares in the offering were sold by DURECT. 
Nov 08, 2013 DURECT Announces Pricing of Public Offering of Common Stock
CUPERTINO, Calif. , Nov. 8, 2013 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced the pricing of an underwritten public offering of 7,142,858 shares of its common stock, offered at a price of $1.40 per share to the public.  The gross proceeds to DURECT from this offering are
Nov 07, 2013 DURECT Announces Proposed Public Offering of Common Stock
CUPERTINO, Calif. , Nov. 7, 2013 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it is offering, subject to market conditions, shares of its common stock in an underwritten public offering. DURECT anticipates using the net proceeds from this offering for general corporate
Nov 04, 2013 DURECT Corporation Announces Third Quarter 2013 Financial Results and Update of Programs
CUPERTINO, Calif. , Nov. 4, 2013 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the third quarter of 2013. Total revenues were $3.0 million for the three months ended September 30, 2013 as compared to $3.8 million for the three months ended September 30 ,
Oct 28, 2013 DURECT Corporation Invites You to Join its Third Quarter 2013 Earnings Conference Call
CUPERTINO, Calif. , Oct. 28, 2013 /PRNewswire/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) third quarter 2013 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Monday, November 4, 2013 at 4:30 pm Eastern
Oct 22, 2013 Pfizer Proceeding with REMOXY® Development
CUPERTINO, Calif. , Oct. 22, 2013 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) announced today that Pfizer Inc. (NYSE: PFE) has stated that, having achieved technical milestones related to manufacturing, they will continue the development program for REMOXY ® (oxycodone) Extended-Release
Sep 27, 2013 DURECT Announces Changes to its Board of Directors
Jay Shepard to join the Board effective September 26, 2013 Michael Casey to retire from the Board effective December 31, 2013 CUPERTINO, Calif. , Sept. 27, 2013 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that Jay Shepard will join its Board of Directors effective September 26
Sep 03, 2013 DURECT to Participate in Upcoming Healthcare Conferences
CUPERTINO, Calif. , Sept. 3, 2013 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) announced today that management is scheduled to present at three upcoming healthcare conferences. (Logo: http://photos.prnewswire.com/prnh/20020717/DRRXLOGO ) James E.
Aug 05, 2013 DURECT Corporation Announces Second Quarter 2013 Financial Results and Update of Programs
CUPERTINO, Calif. , Aug. 5, 2013 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the second quarter of 2013. Total revenues were $3.9 million for the three months ended June 30, 2013 as compared to $4.8 million for the three months ended June 30 , 2012.  Net
Aug 01, 2013 DURECT Announces Selection with Orient PHARMA of Lead Formulation for ORADUR®-Methylphenidate
CUPERTINO, Calif. , Aug. 1, 2013 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it and its collaborator Orient PHARMA Co., Ltd. , a diversified multinational pharmaceutical, healthcare and consumer products company with headquarters in Taiwan , have selected a lead
Jul 26, 2013 DURECT Corporation Invites You to Join its Second Quarter 2013 Earnings Conference Call
CUPERTINO, Calif. , July 26, 2013 /PRNewswire/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) second quarter 2013 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Monday, August 5, 2013 at 4:30 pm Eastern
Jun 20, 2013 DURECT Announces FDA Acceptance of New Drug Application (NDA) Submission for POSIDUR® (SABER®-Bupivacaine)
CUPERTINO, Calif. , June 20, 2013 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) today announced that the New Drug Application (NDA) for the investigational product POSIDUR (SABER-Bupivacaine) has been accepted by the U.S. Food and Drug Administration ( FDA ) indicating that the application is
May 10, 2013 DURECT Announces Update on Remoxy®
CUPERTINO, Calif. , May 10, 2013 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that Pfizer has provided an update on Remoxy as part of their Form 10-Q filing.  Pfizer's disclosure is as follows: "In 2005, King Pharmaceuticals, Inc.
May 02, 2013 DURECT Corporation Announces First Quarter 2013 Financial Results and Update of Programs
CUPERTINO, Calif. , May 2, 2013 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the first quarter of 2013. Total revenues were $4.2 million and net loss was $5.2 million for the three months ended March 31 , 2013.  For comparison, total GAAP revenue was $41.2
Apr 24, 2013 DURECT Corporation Invites You to Join its First Quarter 2013 Earnings Conference Call
CUPERTINO, Calif. , April 24, 2013 /PRNewswire/ -- In conjunction with DURECT Corporation 's (Nasdaq: DRRX) first quarter 2013 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Thursday, May 2, 2013 at 4:30 pm Eastern
Apr 16, 2013 DURECT Announces Submission of New Drug Application for POSIDUR™ (SABER®-Bupivacaine)
CUPERTINO, Calif. , April 16, 2013 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration ( FDA ) for the investigational product POSIDUR (SABER ® -Bupivacaine).  POSIDUR is a post-operative pain
Feb 28, 2013 DURECT Corporation Announces Fourth Quarter 2012 Financial Results and Update of Programs
CUPERTINO, Calif., Feb. 28, 2013 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended December 31, 2012 . Total revenues were $3.3 million for the three months ended December 31, 2012 as compared to $8.9 million for the three months ended
Feb 22, 2013 DURECT Corporation Invites You to Join its Fourth Quarter 2012 Earnings Conference Call
CUPERTINO, Calif. , Feb. 22, 2013 /PRNewswire/ -- In conjunction with DURECT Corporation 's (Nasdaq: DRRX) fourth quarter 2012 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Thursday, February 28, 2013 at 4:30 pm
Feb 05, 2013 DURECT to Participate in Upcoming Healthcare Conferences
CUPERTINO, Calif. , Feb. 5, 2013 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) announced today that management is scheduled to present at two upcoming healthcare conferences.  Matthew J. Hogan , Chief Financial Officer, will present at the BIO CEO & Investor Conference on Tuesday, February
Jan 03, 2013 DURECT Announces Positive Results from Relday™ Phase 1 Clinical Trial
CUPERTINO, Calif. , Jan. 3, 2013 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced that its licensee, Zogenix Inc. (Nasdaq: ZGNX), today reported positive single-dose pharmacokinetic (PK) results from the Phase 1 clinical trial of Relday ™ , an investigational candidate of a proprietary,
Dec 06, 2012 DURECT Announces Pricing of Public Offering of Common Stock
CUPERTINO, Calif. , Dec. 6, 2012 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) today announced the pricing of an underwritten public offering of 14 million shares of its common stock, offered at a price of $0.90 per share to the public.  The gross proceeds to DURECT from this offering are
Nov 13, 2012 DURECT to Participate in Upcoming Healthcare Conferences
CUPERTINO, Calif. , Nov. 13, 2012 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that management is scheduled to present at two upcoming healthcare conferences.  James E. Brown , President and CEO, will present at the Credit Suisse 2012 Healthcare Conference on Thursday, November
Nov 05, 2012 DURECT Corporation Announces Third Quarter 2012 Financial Results and Update of Programs
CUPERTINO, Calif. , Nov. 5, 2012 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended September 30, 2012 . Total revenues were $3.8 million for the three months ended September 30, 2012 as compared to $8.1 million for the three months ended
Oct 30, 2012 DURECT Corporation Invites You to Join its Third Quarter 2012 Earnings Conference Call
CUPERTINO, Calif. , Oct. 30, 2012 /PRNewswire/ -- In conjunction with DURECT Corporation 's (Nasdaq: DRRX) third quarter 2012 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Monday, November 5, 2012 at 4:30 pm
Aug 21, 2012 DURECT to Participate in Upcoming Healthcare Conferences
CUPERTINO, Calif. , Aug. 21, 2012 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) announced today that management is scheduled to present at two upcoming healthcare conferences.  (Logo: http://photos.prnewswire.com/prnh/20020717/DRRXLOGO ) Matt Hogan , Chief Financial Officer, will present at
Aug 06, 2012 DURECT Corporation Announces Second Quarter 2012 Financial Results and Update of Programs
CUPERTINO, Calif. , Aug. 6, 2012 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended June 30, 2012 . Total revenues were $4.8 million for the three months ended June 30, 2012 as compared to $7.8 million for the three months ended June 30 ,
Aug 06, 2012 DURECT Announces Intent to Submit NDA for POSIDUR™ for Post-Operative Analgesia
CUPERTINO, Calif. , Aug. 6, 2012 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it has completed its pre-NDA communications  with the United States Food and Drug Administration ( FDA ) regarding POSIDUR ™ (SABER ® -Bupivacaine).  Through this process, DURECT has received
Jul 26, 2012 DURECT Corporation Invites You to Join its Second Quarter 2012 Earnings Conference Call
CUPERTINO, Calif. , July 26, 2012 /PRNewswire/ -- In conjunction with DURECT Corporation 's (Nasdaq: DRRX) second quarter 2012 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Monday, August 6, 2012 at 4:30 pm Eastern
May 03, 2012 DURECT Corporation Announces First Quarter 2012 Financial Results and Update of Programs
CUPERTINO, Calif. , May 3, 2012 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended March 31, 2012 . Excluding the accelerated recognition of deferred revenue described below, DURECT 's reported revenues would have been $5.8 million for
May 03, 2012 DURECT Announces Issuance of U.S. Patents Covering ORADUR® Technology
New Patents Broaden and Extend Protection for REMOXY® and other ORADUR-based Opioids CUPERTINO, Calif. , May 3, 2012 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced the issuance of four patents by the United States Patent and Trademark Office (USPTO) covering DURECT 's ORADUR
Apr 25, 2012 DURECT Corporation Invites You to Join its First Quarter 2012 Earnings Conference Call
CUPERTINO, Calif., April 25, 2012 /PRNewswire via COMTEX/ --In conjunction with DURECT Corporation's (Nasdaq: DRRX) first quarter 2012 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Thursday, May 3, 2012 at 4:30 pm
Mar 29, 2012 DURECT Receives Back U.S. and Canadian Product Rights to POSIDUR™
CUPERTINO, Calif. , March 29, 2012 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) today reported that Hospira, Inc. has given notice that it is returning its development and commercialization rights to POSIDUR™ (SABER®-Bupivacaine) in the U.S.
Mar 01, 2012 DURECT Corporation Announces Fourth Quarter and Year End 2011 Financial Results
CUPERTINO, Calif. , March 1, 2012 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months and year ended December 31, 2011 . Total revenues were $8.9 million for the three months ended December 31, 2011 , up from $8.5 million for the three months
Feb 24, 2012 DURECT Corporation Invites You to Join Its Fourth Quarter 2011 Earnings Conference Call
CUPERTINO, Calif. , Feb. 24, 2012 /PRNewswire/ -- In conjunction with DURECT Corporation 's (Nasdaq: DRRX) fourth quarter 2011 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Thursday, March 1, 2012 at 4:30 pm
Feb 23, 2012 DURECT to Participate in Upcoming Healthcare Conferences
CUPERTINO, Calif. , Feb. 23, 2012 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) announced today that management is scheduled to present at two upcoming healthcare conferences. (Logo: http://photos.prnewswire.com/prnh/20020717/DRRXLOGO ) James E.
Feb 07, 2012 DURECT to Present at the BIO CEO & Investor Conference
CUPERTINO, Calif. , Feb. 7, 2012 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that Matt Hogan (Chief Financial Officer) will be presenting at the BIO CEO & Investor Conference on Tuesday, February 14 at 10:30 a.m. Eastern Time .  The conference is being held at the
Jan 30, 2012 DURECT Receives Back European Product Rights to POSIDUR™
CUPERTINO, Calif. , Jan. 30, 2012 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today reported that Takeda (through Nycomed) has given notice that it is returning its development and commercialization rights to POSIDUR™ (SABER™-Bupivacaine) in Europe and their other licensed territories. 
Jan 05, 2012 DURECT Announces Top-line Data from BESST (POSIDUR® U.S. Pivotal Phase III Trial)
Conference call to be held January 6 at 8:30 a.m. ET CUPERTINO, Calif. , Jan. 5, 2012 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) announced today top-line results from the U.S. pivotal Phase III clinical study for POSIDUR® known as BESST (Bupivacaine Effectiveness and Safety in SABER
Nov 07, 2011 DURECT Corporation to Participate in Upcoming Healthcare Conferences
CUPERTINO, Calif., Nov. 7, 2011 /PRNewswire via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today that management is scheduled to present at two upcoming healthcare conferences. (Logo: http://photos.prnewswire.com/prnh/20020717/DRRXLOGO ) Jim Brown , President and CEO, will present at
Nov 03, 2011 DURECT Corporation Announces Third Quarter 2011 Financial Results and Update of Programs
CUPERTINO, Calif., Nov. 3, 2011 /PRNewswire via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended September 30, 2011 . Total revenues were $8.1 million for the three months ended September 30, 2011 and 2010.
Oct 26, 2011 DURECT Corporation Invites You to Join its Third Quarter 2011 Earnings Conference Call
CUPERTINO, Calif., Oct. 26, 2011 /PRNewswire via COMTEX/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) third quarter 2011 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Thursday, November 3, 2011 at
Sep 06, 2011 DURECT Completes Enrollment in Pivotal U.S. Phase III Trial for POSIDUR® (BESST)
CUPERTINO, Calif., Sept. 6, 2011 /PRNewswire via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today the dosing of the last patient in the U.S. pivotal Phase III clinical study for POSIDUR® known as BESST (Bupivacaine Effectiveness and Safety in SABER trial).
Aug 31, 2011 DURECT Corporation to Participate in Upcoming Healthcare Conferences
CUPERTINO, Calif., Aug. 31, 2011 /PRNewswire via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today that management is scheduled to present at three upcoming healthcare conferences. (Logo: http://photos.prnewswire.com/prnh/20020717/DRRXLOGO ) Jim Brown , President and CEO, will present at
Aug 04, 2011 DURECT Corporation Announces Second Quarter 2011 Financial Results and Update of Programs
CUPERTINO, Calif., Aug. 4, 2011 /PRNewswire via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended June 30, 2011 . Total revenues increased to $7.8 million for the three months ended June 30, 2011 from $7.3 million for the three months ended
Jul 28, 2011 DURECT Corporation Invites You to Join its Second Quarter 2011 Earnings Conference Call
CUPERTINO, Calif., July 28, 2011 /PRNewswire via COMTEX/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) second quarter 2011 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Thursday, August 4, 2011 at 4:30
Jul 12, 2011 Zogenix and DURECT Announce Development and License Agreement for Antipsychotic Product Candidate
Zogenix to Develop and Commercialize Proprietary Long-Acting Risperidone Formulation for Needle-Free Subcutaneous Administration Using the DosePro(R) Delivery System and DURECT's SABER(TM) Depot Technology Potential to Address $16 Billion World-Wide Antipsychotics Market SAN DIEGO and CUPERTINO,
Jun 24, 2011 Pfizer Receives Complete Response Letter from FDA for REMOXY®
CUPERTINO, Calif., June 24, 2011 /PRNewswire via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) today reported that Pfizer Inc. (NYSE: PFE) has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for REMOXY®, a controlled-release
Jun 03, 2011 DURECT to Present at the Jefferies Healthcare Conference
CUPERTINO, Calif., June 3, 2011 /PRNewswire via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today that Jim Brown , President and CEO, will be presenting at the Jefferies Healthcare Conference on Tuesday, June 7 at 4:30 p.m. Eastern time . The conference is being held at the Grand Hyatt
Jun 02, 2011 DURECT Announces Resignation of Chief Medical Officer
CUPERTINO, Calif., June 2, 2011 /PRNewswire via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today that Dr. Joseph Stauffer , Chief Medical Officer and Executive Vice President, Corporate Strategy has resigned effective June 21, 2011 to pursue other opportunities. Dr.
May 12, 2011 DURECT to Present at the UBS Global Specialty Pharmaceuticals Conference
CUPERTINO, Calif., May 12, 2011 /PRNewswire via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today that Matt Hogan , Chief Financial Officer, will be presenting at the UBS Global Specialty Pharmaceuticals Conference on Tuesday, May 24 at 10:00 a.m. London Time.
May 05, 2011 DURECT Corporation Announces First Quarter 2011 Financial Results and Update of Programs
CUPERTINO, Calif., May 5, 2011 /PRNewswire via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended March 31, 2011 . Total revenues increased to $8.6 million for the three months ended March 31, 2011 from $7.7 million for the three months ended
Apr 28, 2011 DURECT Corporation Invites You to Join its First Quarter 2011 Earnings Conference Call
CUPERTINO, Calif., April 28, 2011 /PRNewswire via COMTEX/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) first quarter 2011 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Thursday, May 5, 2011 at 4:30 pm
Apr 11, 2011 DURECT Announces ELADUR(R) (TRANSDUR(R)-Bupivacaine) Phase II Study Results in Chronic Low Back Pain
CUPERTINO, Calif., April 11, 2011 /PRNewswire via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today top-line results from a Phase II clinical trial in chronic low back pain for ELADUR(R) (TRANSDUR(R)-Bupivacaine), DURECT's proprietary investigational transdermal bupivacaine pain patch.
Mar 02, 2011 DURECT Corporation Announces Fourth Quarter and Year End 2010 Financial Results
Mar 01, 2011 DURECT to Present at Cowen and Company Health Care Conference
CUPERTINO, Calif., March 1, 2011 /PRNewswire via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today that Dr. James E. Brown , President and Chief Executive Officer, will be presenting at the Cowen and Company 31st Annual Healthcare Conference on Monday, March 7 at 1:00 pm Eastern Time .
Feb 24, 2011 DURECT Corporation Invites You to Join its Fourth Quarter 2010 Earnings Conference Call
CUPERTINO, Calif., Feb. 24, 2011 /PRNewswire via COMTEX/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) fourth quarter 2010 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Wednesday, March 2, 2011 at 4:30
Feb 09, 2011 DURECT Reports Data From European Phase IIb Shoulder Study of POSIDUR(TM) (SABER(TM)-Bupivacaine) and Amendment of the Nycomed Agreement
CUPERTINO, Calif., Feb. 9, 2011 /PRNewswire via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today results from a European Phase IIb shoulder clinical trial conducted by Nycomed of POSIDUR(TM) (also known as SABER(TM)-bupivacaine or Optesia(TM) in the E.U.), a proprietary product under
Feb 08, 2011 DURECT Announces Launch of First FDA Approved SABER(TM)-Injectable Peptide Product
Covers an Animal Health Application CUPERTINO, Calif., Feb. 8, 2011 /PRNewswire via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) today reported that its collaborator, CreoSalus, Inc., has launched commercial sales of its Food and Drug Administration (FDA) approved product known as SucroMate(TM)
Feb 07, 2011 DURECT to Present at the BIO CEO & Investor Conference
CUPERTINO, Calif., Feb. 7, 2011 /PRNewswire via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today that Matt Hogan (Chief Financial Officer) will be presenting at the BIO CEO & Investor Conference on Monday, February 14 at 9:30 a.m. Eastern Time .
Jan 27, 2011 REMOXY(R) New Drug Application Accepted by the FDA with PDUFA Goal Date of June 23, 2011
CUPERTINO, Calif., Jan. 27, 2011 /PRNewswire via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) today reported that the U.S. Food and Drug Administration (FDA) has accepted the resubmission of the New Drug Application (NDA) for REMOXY(R) by King Pharmaceuticals, Inc.
Dec 27, 2010 REMOXY(R) New Drug Application Resubmitted
CUPERTINO, Calif., Dec. 27, 2010 /PRNewswire via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) today reported that King Pharmaceuticals, Inc. (NYSE: KG) and Pain Therapeutics, Inc. (Nasdaq: PTIE) have announced that King has resubmitted a New Drug Application (NDA) for REMOXY(R) to the U.S.
Nov 22, 2010 DURECT to Present at the Piper Jaffray 2010 Health Care Conference
CUPERTINO, Calif., Nov. 22, 2010 /PRNewswire via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today that Matt Hogan (Chief Financial Officer) and Joe Stauffer (Chief Medical Officer) will be presenting at the 22nd Annual Piper Jaffray Health Care Conference on Wednesday, December 1 at
Nov 08, 2010 DURECT to Present at the Credit Suisse 2010 Healthcare Conference
CUPERTINO, Calif., Nov. 8, 2010 /PRNewswire via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today that James E. Brown, President and CEO, will be presenting at the Credit Suisse 2010 Healthcare Conference on Friday, November 12 at 8:30 a.m. Pacific Time.
Nov 03, 2010 DURECT Corporation Announces Third Quarter 2010 Financial Results
CUPERTINO, Calif., Nov. 3, 2010 /PRNewswire via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended September 30, 2010. Total revenues were $8.1 million for the three months ended September 30, 2010 compared to $8.4 million for the three months
Nov 02, 2010 DURECT Awarded $733,438 in Grants Under the Patient Protection and Affordable Care Program
CUPERTINO, Calif., Nov. 2, 2010 /PRNewswire via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it has been awarded grants totaling $733,438 to advance our programs in post-operative pain relief, attention deficit disorder (ADHD) and chronic diseases treated with biologic agents.
Oct 27, 2010 DURECT Corporation Invites You to Join its Third Quarter 2010 Earnings Conference Call
CUPERTINO, Calif., Oct 27, 2010 /PRNewswire via COMTEX/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) third quarter 2010 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Wednesday, November 3, 2010 at
Sep 07, 2010 DURECT Corporation to Participate in Upcoming Healthcare Conferences
CUPERTINO, Calif., Sep 7, 2010 (GlobeNewswire via COMTEX) -- DURECT Corporation (Nasdaq:DRRX) announced today that management is scheduled to present at three upcoming healthcare conferences. -- Joe Stauffer, Chief Medical Officer and EVP-Corporate Strategy, will deliver a talk entitled "FDA
Aug 04, 2010 DURECT Corporation Announces Second Quarter 2010 Financial Results
CUPERTINO, Calif., Aug 04, 2010 /PRNewswire via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended June 30, 2010. Total revenues were $7.3 million for the three months ended June 30, 2010 compared to $4.9 million for the three months ended June
Jul 29, 2010 DURECT Corporation Invites You to Join Its Second Quarter 2010 Earnings Conference Call
CUPERTINO, Calif., July 29, 2010 /PRNewswire via COMTEX/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) second quarter 2010 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Wednesday, August 4, 2010 at
Jul 28, 2010 DURECT to Present at the BMO Capital Markets Focus on Healthcare Conference
CUPERTINO, Calif., July 28, 2010 /PRNewswire via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today that Matthew J. Hogan, Chief Financial Officer, will be presenting at the BMO Capital Markets 10th Annual Focus on Healthcare Conference on Thursday, August 5 at 1:45 p.m. Eastern Time.
Jul 01, 2010 DURECT Corporation Secures $50 Million Committed Equity Financing Facility
CUPERTINO, Calif., July 1, 2010 /PRNewswire via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it has secured a committed equity financing facility under which it may sell up to $50 million of its registered common stock to Azimuth Opportunity Ltd. for a term of 24 months.
Jun 16, 2010 DURECT Reports Data From European Phase IIb Hysterectomy Study of POSIDUR(TM) (SABER(TM)-Bupivacaine)
CUPERTINO, Calif., June 16, 2010 /PRNewswire via COMTEX/ --DURECT Corporation (Nasdaq: DRRX) announced today results from a European Phase IIb hysterectomy clinical trial conducted by Nycomed of POSIDUR(TM) (also known as SABER(TM)-bupivacaine or Optesia(TM) in the E.U.), a proprietary product
Jun 07, 2010 DURECT Corporation Invites You to Join a Conference Call Today Regarding its POSIDUR(TM) Collaboration with Hospira
CUPERTINO, Calif., June 7, 2010 /PRNewswire via COMTEX/ --In conjunction with the announcement of a POSIDUR(TM) (SABER(TM)-Bupivacaine) collaboration between DURECT Corporation (Nasdaq: DRRX) and Hospira, Inc. (NYSE: HSP), you are invited to listen to a conference call that will be broadcast live
Jun 07, 2010 Hospira and DURECT Sign Agreement to Develop and Commercialize POSIDUR™(SABER™-Bupivacaine) in the U.S. and Canada
-- Product would strengthen Hospira’s acute-care portfolio, offer novel pain treatment -- LAKE FOREST, Ill., and CUPERTINO, Calif., June 7, 2010 -- Hospira, Inc. (NYSE: HSP), a global specialty pharmaceutical and medication delivery company, and DURECT Corporation, a specialty pharmaceutical
Jun 01, 2010 DURECT to Present at the Jefferies Global Life Sciences Conference
CUPERTINO, Calif., June 1, 2010 /PRNewswire via COMTEX/ --DURECT Corporation (Nasdaq: DRRX) announced today that James E. Brown, President and Chief Executive Officer, will be presenting at the Jefferies Global Life Sciences Conference on Thursday, June 10 at 10:30 a.m. Eastern Time.
May 13, 2010 DURECT to Present at the Rodman & Renshaw Global Healthcare Conference
CUPERTINO, Calif., May 13, 2010 /PRNewswire via COMTEX/ --DURECT Corporation (Nasdaq: DRRX) announced today that Matt Hogan, Chief Financial Officer, will be presenting at the Rodman & Renshaw Global Healthcare Conference on Monday, May 17 at 4:30 p.m. London time (11:30 am Eastern Time).
May 10, 2010 DURECT Corporation Announces First Quarter 2010 Financial Results
CUPERTINO, Calif., May 10, 2010 /PRNewswire via COMTEX/ --DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended March 31, 2010. Total revenues were $7.7 million for the three months ended March 31, 2010 and $6.2 million for the three months ended March 31,
May 04, 2010 DURECT Corporation Invites You to Join Its First Quarter 2010 Earnings Conference Call
CUPERTINO, Calif., May 4, 2010 /PRNewswire via COMTEX/ --In conjunction with DURECT Corporation's (Nasdaq: DRRX) first quarter 2010 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Monday, May 10, 2010 at 4:30 pm
Apr 07, 2010 DURECT Corporation Announces Commencement of Phase IIb ELADUR(TM) (TRANSDUR(TM)-Bupivacaine) Clinical Trial by King Pharmaceuticals
CUPERTINO, Calif., April 7, 2010 /PRNewswire via COMTEX/ --DURECT Corporation (Nasdaq: DRRX) announced today that its licensee, King Pharmaceuticals (NYSE: KG), has begun a Phase IIb clinical trial to evaluate ELADUR(TM) (TRANSDUR(TM)-Bupivacaine) for the treatment of chronic low back pain.
Mar 17, 2010 DURECT to Present at the Barclays Capital Global Healthcare Conference
CUPERTINO, Calif., March 17, 2010 /PRNewswire via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today that Matt Hogan, Chief Financial Officer, will be presenting at the Barclays Capital Global Healthcare Conference on Wednesday, March 24 at 8:30 am Eastern Time.
Mar 01, 2010 DURECT to Present at the Cowen and Company Healthcare Conference
CUPERTINO, Calif., March 1, 2010 /PRNewswire via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today that Dr. James E. Brown, President and Chief Executive Officer, will be presenting at the Cowen and Company 30th Annual Healthcare Conference on Monday, March 8 at 3:15 pm Eastern Time.
Feb 24, 2010 DURECT Corporation Announces Fourth Quarter and Year End 2009 Financial Results
CUPERTINO, Calif., Feb 24, 2010 /PRNewswire via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months and year ended December 31, 2009. Total revenues were $4.9 million for the three months ended December 31, 2009 and $7.7 million for the three months
Feb 22, 2010 DURECT and Nycomed Amend POSIDUR(TM) License Agreement to Separate Funding and Control of U.S. and E.U. Clinical Programs and to Expand Territory
CUPERTINO, Calif., Feb 22, 2010 /PRNewswire via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today that Nycomed and DURECT have amended the Development and License Agreement entered into between the parties in 2006 covering the development and commercialization of POSIDUR(TM) (also known
Feb 17, 2010 DURECT Corporation Invites You to Join Its Fourth Quarter 2009 Earnings Conference Call
CUPERTINO, Calif., Feb 17, 2010 /PRNewswire via COMTEX/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) fourth quarter 2009 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Wednesday, February 24, 2010 at
Jan 19, 2010 DURECT Initiates U.S. Pivotal Phase III POSIDUR(TM) Clinical Trial
BESST (Bupivacaine Effectiveness and Safety in SABER(TM) Trial) Targets Post-Surgical Pain CUPERTINO, Calif., Jan 19, 2010 /PRNewswire via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it has begun dosing patients in its U.S. pivotal Phase III clinical trial to evaluate
Dec 17, 2009 DURECT Reports Positive Phase IIb Data from POSIDUR(TM) Clinical Program
CUPERTINO, Calif., Dec 17, 2009 /PRNewswire-FirstCall via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today positive results from a 60 patient Phase IIb clinical trial of POSIDUR(TM), a proprietary product under development for the treatment of post-surgical pain.
Nov 23, 2009 DURECT to Present at the 21st Annual Piper Jaffray Health Care Conference
CUPERTINO, Calif. , Nov. 23 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that Matt Hogan , Chief Financial Officer, and Joe Stauffer , Chief Medical Officer, will be presenting at the 21st Annual Piper Jaffray Health Care Conference on Tuesday, December 1 at 3:30 pm
Oct 29, 2009 DURECT Corporation Announces Third Quarter 2009 Financial Results
CUPERTINO, Calif., Oct 29, 2009 /PRNewswire-FirstCall via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended September 30, 2009. Total revenues were $8.4 million for the three months ended September 30, 2009, compared to $6.6 million for the
Oct 26, 2009 DURECT Corporation Invites You to Join its Third Quarter 2009 Earnings Conference Call
CUPERTINO, Calif. , Oct. 26 /PRNewswire-FirstCall/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) third quarter 2009 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Thursday, October 29, 2009 at 4:30 pm
Sep 17, 2009 DURECT Corporation to Participate in Upcoming Healthcare Conferences
CUPERTINO, Calif. , Sept. 17 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that management is scheduled to present at two upcoming healthcare conferences. (Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO ) -- Matt Hogan , Chief Financial Officer, will
Sep 11, 2009 DURECT Announces Sale of 4,444,444 Shares of Common Stock, Raising Proceeds of $10 Million
CUPERTINO, Calif. , Sept. 11 /PRNewswire-FirstCall/ -- -- DURECT Corporation (Nasdaq: DRRX) today reported that it has entered into a privately negotiated transaction to sell 4,444,444 primary shares of common stock to affiliates of Venrock at a price of $2.25 per share, raising net proceeds to
Aug 27, 2009 DURECT Signs Long Term Excipient Supply Agreement With King Pharmaceuticals for REMOXY(R)
CUPERTINO, Calif. , Aug. 27 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) today reported that it has signed an exclusive long term excipient supply agreement with respect to REMOXY(R) with King Pharmaceuticals, Inc. (NYSE: KG). This agreement stipulates the terms and conditions under
Aug 18, 2009 DURECT Announces License of ADHD Drug Candidate in Selected Asian and South Pacific Countries to Orient Pharma
CUPERTINO, Calif., Aug 18, 2009 /PRNewswire-FirstCall via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it has signed a development and license agreement with Orient Pharma Co., Ltd., a diversified multinational pharmaceutical, healthcare and consumer products company with
Aug 03, 2009 DURECT Corporation Announces Second Quarter 2009 Financial
Results CUPERTINO, Calif., Aug 03, 2009 /PRNewswire-FirstCall via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended June 30, 2009. Total revenues were $4.9 million for the three months ended June 30, 2009, compared to $6.3 million for the same
Jul 28, 2009 DURECT to Present at the BMO Capital Markets Healthcare Conference
CUPERTINO, Calif., July 28 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that Matthew Hogan , Chief Financial Officer, will be presenting at the BMO Capital Markets 9th Annual Focus on Healthcare Conference on Wednesday, August 5 at 4:00 pm Eastern Time .
Jul 27, 2009 DURECT Corporation Invites You to Join Its Second Quarter 2009 Earnings Conference Call
CUPERTINO, Calif., July 27, 2009 /PRNewswire-FirstCall via COMTEX/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) second quarter 2009 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Monday, August 3, 2009
Jul 07, 2009 REMOXY(R) NDA Update
CUPERTINO, Calif., July 7 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) today reported that King Pharmaceuticals, Inc. (NYSE: KG) and Pain Therapeutics, Inc. (Nasdaq: PTIE) have announced that King met with the Food and Drug Administration (FDA) on July 2, 2009 to discuss the Complete
Jun 16, 2009 DURECT Appoints Dr. Joseph Stauffer as Chief Medical Officer and Executive Vice President, Corporate Strategy
CUPERTINO, Calif., June 16 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that Dr. Joseph Stauffer has joined DURECT as Chief Medical Officer and Executive Vice President, Corporate Strategy. (Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO ) "Dr.
May 06, 2009 DURECT Corporation Announces First Quarter 2009 Financial Results
CUPERTINO, Calif., May 6 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended March 31, 2009 . Total revenues were $6.2 million for the three months ended March 31, 2009 , compared to $6.4 million for the same period in 2008.
Apr 28, 2009 DURECT Corporation Invites You to Join its First Quarter 2009 Earnings Conference Call
CUPERTINO, Calif., April 28 /PRNewswire-FirstCall/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) first quarter 2009 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Wednesday, May 6, 2009 at 4:30 pm
Mar 16, 2009 DURECT Reports Positive Phase IIb Data from TRANSDU(TM)-Sufentanil Clinical Program
CUPERTINO, Calif., March 16 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today positive results from a 74 patient Phase IIb clinical trial conducted by Endo Pharmaceuticals of TRANSDUR(TM)-Sufentanil, a proprietary seven day patch under development for the treatment of
Mar 09, 2009 DURECT to Participate in Cowen and Company Healthcare Conference
CUPERTINO, Calif., March 9 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that Matthew Hogan , Chief Financial Officer, will be presenting at the Cowen and Company 29th Annual Healthcare Conference on March 17, 2009 at 8:00 a.m. EDT .
Feb 27, 2009 Endo Pharmaceuticals Returns Product Rights to TRANSDUR(TM)-Sufentanil to DURECT
CUPERTINO, Calif., Feb. 27 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) today reported that Endo Pharmaceuticals (Nasdaq: ENDP) has given notice that it is returning to us Endo's rights in the U.S. and Canada to develop and commercialize TRANSDUR(TM)-Sufentanil, a proprietary
Feb 09, 2009 DURECT Corporation Announces Fourth Quarter and Year End 2008 Financial Results
CUPERTINO, Calif., Feb. 9 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months and year ended December 31, 2008 . Total revenues were $6.6 million for the three months ended December 31, 2008 and December 31, 2007 .
Feb 02, 2009 DURECT Corporation Invites You to Join Its Fourth Quarter 2008 Earnings Conference Call
CUPERTINO, Calif., Feb. 2 /PRNewswire-FirstCall/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) fourth quarter 2008 financial results press release, you are invited to listen to the conference call that will be broadcast live over the Internet on Monday, February 9th, 2009 at 4:30 p.m.
Dec 11, 2008 Pain Therapeutics Receives Complete Response Letter From FDA for REMOXY(R)
CUPERTINO, Calif., Dec. 11 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) today reported that Pain Therapeutics, Inc. (Nasdaq: PTIE) has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for REMOXY(R), an
Nov 26, 2008 DURECT Corporation to Participate in Upcoming Healthcare Conferences
CUPERTINO, Calif., Nov. 26 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that management is scheduled to present at the following upcoming healthcare conferences in New York, NY. -- 20th Annual Piper Jaffray Health Care Conference on Wednesday, December 3rd at 8:00
Nov 03, 2008 DURECT Corporation Announces Third Quarter 2008 Financial Results
CUPERTINO, Calif., Nov. 3 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended September 30, 2008. Total revenues were $6.6 million for the three months ended September 30, 2008, compared to $4.9 million for the same period in
Oct 29, 2008 DURECT's Collaboration With Alpharma Clears HSR Review and Is Effective
CUPERTINO, Calif., Oct. 29 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that the previously announced development and license agreement with Alpharma Ireland Limited, an affiliate of Alpharma Inc. (NYSE: ALO), granting such party the exclusive worldwide rights to
Oct 28, 2008 DURECT Corporation to Participate in Upcoming Healthcare Conferences
CUPERTINO, Calif., Oct. 28 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that management is scheduled to present at the following upcoming healthcare conferences in New York, NY. (Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO) -- Oppenheimer 19th Annual
Oct 27, 2008 DURECT Corporation Invites You to Join Its Third Quarter 2008 Earnings Conference Call
CUPERTINO, Calif., Oct. 27 /PRNewswire-FirstCall/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) third quarter 2008 financial results press release, you are invited to listen to the conference call that will be broadcast live over the Internet on Monday, November 3, 2008 at 4:30 p.m.
Sep 22, 2008 Alpharma to Develop and Commercialize DURECT's ELADUR(TM) Pain Patch
CUPERTINO, Calif., Sept. 22 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it has entered into a development and license agreement with an affiliate of Alpharma Inc. (NYSE: ALO) granting such party the exclusive worldwide rights to develop and commercialize
Sep 15, 2008 DURECT Corporation Presenting at the 2008 UBS Global Life Sciences Conference
CUPERTINO, Calif., Sept. 15 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the 2008 UBS Global Life Sciences Conference being held at the Grand Hyatt Hotel in New York. Matthew J. Hogan, Chief Financial Officer, will be presenting at the
Aug 27, 2008 DURECT Announces the IND Submission for a Third Abuse-Resistant Opioid Pain Medication Based on Its ORADUR(TM) Technology
CUPERTINO, Calif., Aug 27, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- DURECT Corporation (Nasdaq: DRRX) today reported that Pain Therapeutics (Nasdaq: PTIE), its licensee, has submitted an Investigational New Drug (IND) application to the U.S.
Aug 12, 2008 REMOXY(R) NDA Filing Accepted by FDA and Priority Review Granted
CUPERTINO, Calif., Aug. 12 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that the US Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) of REMOXY(R) and granted Priority Review. The FDA typically grants Priority Review to drug candidates
Aug 05, 2008 DURECT Corporation Announces Second Quarter 2008 Financial Results
CUPERTINO, Calif., Aug. 5 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended June 30, 2008. Total revenues were $6.3 million for the three months ended June 30, 2008, compared to $13.4 million for the same period in 2007.
Jul 30, 2008 DURECT Corporation Invites You to Join Its Second Quarter 2008 Earnings Conference Call
CUPERTINO, Calif., July 30 /PRNewswire-FirstCall/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) second quarter 2008 financial results press release, you are invited to listen to the conference call that will be broadcast live over the Internet on Wednesday, August 6, 2008 at 9:00 a.m.
Jun 30, 2008 ELADUR(TM) Development Update: DURECT Receives Orphan Drug Designation for Bupivacaine for Post-Herpetic Neuralgia
CUPERTINO, CA, June 30, 2008 / PRNewswire-First Call via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today that the US Food and Drug Administration (FDA) has granted to DURECT orphan drug designation for bupivacaine for relief of persistent pain associated with post-herpetic neuralgia
Jun 17, 2008 DURECT's Convertible Notes Exchange into Equity at Maturity
CUPERTINO, Calif., June 17 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that the remaining $23.6 million in 6.25% Convertible Notes had been exchanged by the holders at their maturity date into approximately 7.5 million shares, per the original terms of the indenture.
Jun 10, 2008 New Drug Application Submitted for Remoxy(TM) (ORADUR(TM)-Based Oxycodone)
CUPERTINO, Calif., June 10 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that a New Drug Application (NDA) for Remoxy(TM) (ORADUR(TM)-based oxycodone) has been submitted to the U.S. Food and Drug Administration (FDA). Remoxy, an investigational drug, is a long acting
Jun 06, 2008 DURECT Corporation to Participate in Upcoming Healthcare Conferences
CUPERTINO, Calif., June 6 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that management is scheduled to present at three upcoming life sciences conferences in New York, NY. -- Needham & Company's Biotechnology and Medical Technology Conference on Thursday, June 12th at
May 21, 2008 DURECT Corporation Presenting at the 2008 UBS Global Generic and Specialty Pharmaceuticals Conference
CUPERTINO, Calif., May 21 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the 2008 UBS Global Generic and Specialty Pharmaceuticals Conference being held at the Waldorf Hilton Hotel in London. Matthew J.
May 07, 2008 DURECT Corporation Announces First Quarter 2008 Financial Results
CUPERTINO, Calif., May 7 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended March 31, 2008. Total revenues were $6.4 million for the three months ended March 31, 2008, compared to $5.7 million for the same period in 2007.
Apr 29, 2008 DURECT Corporation Invites You to Join Its First Quarter 2008 Earnings Conference Call
CUPERTINO, Calif., April 29 /PRNewswire-FirstCall/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) first quarter 2008 financial results press release, you are invited to listen to the conference call that will be broadcast live over the Internet on Wednesday, May 7th, 2008 at 4:30 p.m.
Apr 22, 2008 DURECT to Participate in Morgan Stanley Global Healthcare Conference
CUPERTINO, Calif., April 22 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that James Brown, President and Chief Executive Officer, will be presenting at the Morgan Stanley 2008 Global Healthcare Unplugged Conference on April 30, 2008 at 8:30 a.m. ET.
Apr 07, 2008 DURECT Provides Update on CHRONOGESIC(R) Research Program
CUPERTINO, Calif., April 7, 2008 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that Endo Pharmaceuticals has stated that it intends to return the rights to CHRONOGESIC(R) licensed from DURECT Corporation for the U.S. and Canada.
Mar 11, 2008 DURECT to Participate in Cowen Annual Healthcare Conference
CUPERTINO, Calif., March 11 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that James Brown, President and Chief Executive Officer, will be presenting at the Cowen and Company 28th Annual Healthcare Conference on March 17, 2008 at 4:00 p.m. EST.
Feb 29, 2008 DURECT to Participate in Susquehanna Financial Healthcare Conference
CUPERTINO, Calif., Feb. 29 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that James Brown, President and Chief Executive Officer, will be presenting at the SIGnificant Investment Options in Healthcare conference hosted by Susquehanna Financial Group on Tuesday, March
Feb 05, 2008 DURECT Corporation Announces Fourth Quarter and Year End 2007 Financial Results
CUPERTINO, Calif., Feb. 5 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months and year ended December 31, 2007. Total revenues were $6.6 million for the three months ended December 31, 2007, compared to $5.4 million for the same period
Feb 04, 2008 DURECT to Present at BIO CEO Investor Conference 2008
CUPERTINO, Calif., Feb. 4 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that Matthew J. Hogan, Chief Financial Officer, will be presenting at the BIO CEO and Investor Conference to be held at the Waldorf Astoria Hotel in New York on February 11, 2008 at 11:45 a.m.
Jan 31, 2008 DURECT Corporation Invites You to Join Its Fourth Quarter 2007 Earnings Conference Call
CUPERTINO, Calif., Jan. 31 /PRNewswire-FirstCall/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) fourth quarter 2007 financial results press release, you are invited to listen to the conference call that will be broadcast live over the Internet on Wednesday, February 6, 2008 at 9:00
Dec 18, 2007 DURECT Announces Positive ELADUR(TM) Phase IIa Study Results
CUPERTINO, Calif., Dec. 18 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today positive results from a Phase IIa clinical trial for ELADUR(TM), DURECT's proprietary investigational transdermal pain patch. In this study of patients suffering from post-herpetic neuralgia,
Dec 06, 2007 Primary Endpoint of Pivotal Phase III Clinical Trial Achieved for Remoxy(TM)
CUPERTINO, Calif., Dec. 6 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that the pivotal Phase III trial for Remoxy had successfully met its primary endpoint (p (Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO ) "These positive clinical trial results
Dec 04, 2007 DURECT to Present at Upcoming Conferences
CUPERTINO, Calif., Dec. 4 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present a corporate overview and update at two upcoming life sciences conferences in New York, NY. (Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO) -- NYSSA Biotech &
Nov 20, 2007 DURECT to Present at Piper Jaffray Healthcare Conference
CUPERTINO, Calif., Nov. 20 /PRNewswire-FirstCall/ -- via COMTEX -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present a corporate overview and update at the 19th Annual Piper Jaffray Health Care Conference on Tuesday, November 27, 2007 at 4:00 p.m.
Nov 01, 2007 DURECT Corporation Announces Third Quarter 2007 Financial Results
CUPERTINO, Calif., Nov. 1 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended September 30, 2007. Total revenues were $4.9 million for the three months ended September 30, 2007, compared to $5.1 million for the same period in
Nov 01, 2007 DURECT to Present at Upcoming Conferences
CUPERTINO, Calif., Nov 01, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present a corporate overview and update at two upcoming life sciences conferences in New York, NY. -- CIBC World Markets 18th Annual Healthcare Conference
Oct 30, 2007 DURECT Corporation Invites You to Join Its Third Quarter 2007 Earnings Conference Call
CUPERTINO, Calif., Oct. 30 /PRNewswire-FirstCall/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) third quarter 2007 financial results press release, you are invited to listen to the conference call that will be broadcast live over the Internet on Thursday, November 1, 2007 at 4:30 p.m.
Oct 16, 2007 DURECT to Host Webcast in Conjunction with an Analyst's Day on October 17
CUPERTINO, Calif., Oct. 16 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will be hosting an Analyst Event in New York on October 17, 2007 at 12:00 p.m. Eastern Time. A live audio webcast of the presentation will begin at 12:30 p.m.
Oct 04, 2007 DURECT to Present at 2007 BIO Investor Forum
CUPERTINO, Calif., Oct. 4 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that James E. Brown, President and CEO, will be presenting at the 2007 BIO Investor Forum to be held at the Palace Hotel in San Francisco on October 11, 2007 at 10:30 a.m. Pacific Time.
Sep 20, 2007 DURECT to Present at UBS Global Life Sciences Conference
CUPERTINO, Calif., Sept. 20 /PRNewswire-FirstCall/-- DURECT Corporation (Nasdaq: DRRX) announced today that James Brown, President and CEO, will present at the UBS Global Life Sciences Conference in New York on September 27, 2007 at 1:30 p.m. Eastern Time.
Sep 11, 2007 DURECT to Present at Merriman Curhan Ford's Annual Investor Summit
CUPERTINO, Calif., Sept. 11 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that Felix Theeuwes, Chairman and CSO, will present at the 4th annual Merriman Curhan Ford & Co. Investor Summit on September 17, 2007 at 11:45 a.m. Pacific Time.
Aug 29, 2007 DURECT Corporation to Present at the NewsMakers in the Biotech Industry Investment Conference
CUPERTINO, Calif., Aug. 29 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that James E. Brown, President and CEO, will be presenting at the NewsMakers in the Biotech Industry Investment Conference to be held in New York City on September 6, 2007 at 11:30 a.m.
Aug 07, 2007 DURECT Corporation Announces Second Quarter 2007 Financial Results
CUPERTINO, Calif., Aug 07, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended June 30, 2007. Total revenues were $13.4 million for the three months ended June 30, 2007, compared to $6.1 million for
Jul 31, 2007 DURECT Corporation Invites You to Join Its Second Quarter 2007 Earnings Conference Call on the Web
CUPERTINO, Calif., July 31, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) second quarter 2007 financial results press release, you are invited to listen to the conference call that will be broadcast live over the Internet on Tuesday,
Jul 17, 2007 DURECT Reports Positive Results from POSIDUR(TM) Phase IIb Hernia Trial, Triggering $8 million Milestone Payment from Nycomed
Phase IIb Trial Achieves Statistically Significant Reductions in Pain and Total Consumption of Supplemental Opioid Analgesic Medications Versus Placebo CUPERTINO, Calif., July 17 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today positive results from a 122 patient Phase
Jul 11, 2007 Patient Recruitment Completed for Pivotal Phase III Study of Remoxy(TM)
CUPERTINO, Calif., July 11 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) today reported that patient recruitment has been completed in the pivotal Phase III study with Remoxy(TM), an abuse resistant pain medicine under development based on DURECT's patented ORADUR(TM) technology
Jun 27, 2007 DURECT Announces the Initiation of Sufentanil Patch Phase II Study by Endo Pharmaceuticals
CUPERTINO, CA, June 27, 2007/ PRNewswire-First Call via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today that Endo Pharmaceuticals Inc. (Nasdaq: ENDP) has commenced its Phase II clinical program designed to evaluate the conversion of patients being treated with various opioids to
Jun 21, 2007 DURECT Corporation Presenting at the Jefferies Healthcare Conference
CUPERTINO, Calif., June 21, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the Jefferies Healthcare Conference being held in New York City. Matthew J. Hogan, Chief Financial Officer, will be presenting at the
Jun 11, 2007 DURECT Corporation Presenting at the Sixth Annual Needham Biotechnology and Medical Technology Conference
CUPERTINO, Calif., June 11 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the Sixth Annual Biotechnology and Medical Technology Conference being held at the New York Palace Hotel in New York City. Matthew J.
May 17, 2007 DURECT Provides an Update to the Memryte(TM) Program Under Development by Voyager Pharmaceutical Corp
CUPERTINO, Calif., May 17 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that Voyager Pharmaceutical has provided its shareholders with an update on its truncated Phase 3 clinical trial for Memryte, an investigational drug for the treatment of Alzheimer's disease.
May 08, 2007 DURECT Corporation Presenting at the Acumen BioFin Rodman & Renshaw 4th Annual Global Healthcare Conference
CUPERTINO, Calif., May 8 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it would present at the Acumen BioFin Rodman & Renshaw 4th Annual Global Healthcare Conference to be held on May 14-15 at the Le Meridien Beach Plaza Hotel in Monte Carlo, Monaco. James E.
May 07, 2007 DURECT Corporation Announces First Quarter 2007 Financial Results
CUPERTINO, Calif., May 7 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended March 31, 2007. Total revenues were $5.7 million for the three months ended March 31, 2007, compared to $5.2 million for the same period in 2006.
May 01, 2007 DURECT Corporation Presenting at the 2007 UBS Global Generic and Specialty Pharmaceuticals Conference
CUPERTINO, Calif., May 1 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the 2007 UBS Global Generic and Specialty Pharmaceuticals Conference being held at the Grand Hyatt Hotel in New York City. Matthew J.
Apr 30, 2007 DURECT Corporation Invites You to Join Its First Quarter 2007 Earnings Conference Call on the Web
CUPERTINO, Calif., April 30 /PRNewswire-FirstCall/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) first quarter 2007 financial results press release, you are invited to listen to the conference call that will be broadcast live over the Internet on Monday, May 7th 2007 at 4:30 p.m. EDT.
Apr 09, 2007 DURECT Corporation Presenting at the CIBC Biotechnology & Specialty Pharmaceuticals Conference
CUPERTINO, Calif., April 9, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the CIBC Biotechnology & Specialty Pharmaceuticals Conference being held at the Millenium Broadway Hotel in New York City. Matthew J.
Feb 28, 2007 DURECT Corporation to Participate in Upcoming Healthcare Conferences
CUPERTINO, Calif., Feb. 28 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present a corporate overview at three upcoming life sciences conferences in New York, NY. "SIGnificant Investment Options In Healthcare" conference, sponsored by Susquehanna
Feb 12, 2007 DURECT Corporation Presenting at the BIO CEO and Investor Conference
CUPERTINO, Calif., Feb. 12 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the BIO CEO Investor Conference. The conference is being held at The Waldorf Hotel in New York, NY. James E. Brown, DVM, President and CEO, will be presenting at the
Feb 08, 2007 DURECT Corporation Announces Fourth Quarter and Year End 2006 Financial Results
CUPERTINO, Calif., Feb. 8 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months and year ended December 31, 2006. Total revenues were $5.4 million for the three months ended December 31, 2006, compared to $5.8 million for the same period
Feb 05, 2007 DURECT Establishes Corium as Manufacturer of TRANSDUR(TM)-Bupivacaine
CUPERTINO, Calif., Feb. 5 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that we have entered into a long term manufacturing and supply agreement with Corium International, Inc. for TRANSDUR(TM)-Bupivacaine, a transdermal pain patch under development for patients
Jan 30, 2007 DURECT Corporation Invites You to Join Its Fourth Quarter and Year-End 2006 Conference Call on the Web
CUPERTINO, Calif., Jan. 30 /PRNewswire-FirstCall/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) fourth quarter and year-end 2006 financial results press release, you are invited to listen to its conference call that will be broadcast live over the Internet on Thursday, February 8th,
Jan 29, 2007 DURECT Signs POSIDUR(TM) Manufacturing Agreement with Hospira
CUPERTINO, Calif., Jan. 29 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that we have entered into a long term manufacturing and supply agreement with Hospira Worldwide, Inc. ("Hospira") (NYSE: HSP) for POSIDUR(TM), DURECT's post-surgical pain management
Jan 24, 2007 DURECT Amends Agreement with Voyager Governing Memryte(TM)
CUPERTINO, Calif., Jan. 24 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it has amended its development and commercialization agreement with Voyager Pharmaceutical Corporation governing Memryte(TM), an investigational drug under development for the treatment of
Jan 03, 2007 DURECT Starts Phase II Dosing for TRANSDUR(TM)-Bupivacaine (DUR-843)
CUPERTINO, Calif., Jan 03, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- DURECT Corporation (Nasdaq: DRRX) today announced that we have started Phase II dosing in the U.S. under an FDA-accepted Investigational New Drug (IND) application for TRANSDUR(TM)-Bupivacaine (DUR-843), a transdermal
Dec 18, 2006 DURECT Corporation Appoints Dr. Terrence F. Blaschke to Its Board of Directors
CUPERTINO, Calif., Dec. 18 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) today announced that Terrence F. Blaschke, M.D. has joined its Board of Directors. Dr. Blaschke has served on the faculty of Stanford University for over 30 years and is Professor of Medicine and Molecular
Dec 11, 2006 DURECT Corporation Announces Positive Phase I Study Results with New Product in Development
CUPERTINO, Calif., Dec. 11 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it has successfully completed Phase I clinical trials with a new product, DUR-843, which is intended to treat a persistent pain condition. We believe that the persistent pain market remains
Nov 30, 2006 Positive Phase I Results Reported for DURECT's Second Abuse-Resistant Opioid Pain Medicine
CUPERTINO, Calif., Nov. 30 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) today reported positive results from a Phase I clinical trial evaluating an abuse-resistant opioid pain drug candidate based on DURECT's patented ORADUR(TM) technology.
Nov 29, 2006 DURECT and Nycomed Sign $202 Million Agreement to Develop and Commercialize POSIDUR(TM) in Europe and Other Select Countries
CUPERTINO, Calif., Nov. 29 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today the signing of a collaboration agreement with Nycomed, a privately held European pharmaceutical company headquartered in Denmark, whereby the companies will jointly develop DURECT's POSIDUR(TM)
Nov 03, 2006 DURECT Corporation Announces Third Quarter 2006 Financial Results
CUPERTINO, Calif., Nov. 3 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended September 30, 2006. Total revenues were $5.1 million for the three months ended September 30, 2006, compared to $8.6 million for the same period in
Oct 31, 2006 DURECT Corporation to Present at Upcoming Conferences
CUPERTINO, Calif., Oct. 31 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present a corporate overview at three upcoming life sciences conferences in New York, NY. (Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO ) Susquehanna International
Oct 27, 2006 DURECT Corporation Invites You to Join Its Third Quarter 2006 Conference Call on the Web
CUPERTINO, Calif., Oct. 27 /PRNewswire-FirstCall/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) third quarter 2006 financial results press release, you are invited to listen to its conference call that will be broadcast live over the Internet on Friday, November 3rd, 2006 at 8:30 AM
Oct 19, 2006 DURECT Provides an Update to the Memryte(TM) Program Under Development by Voyager Pharmaceutical Corp.
CUPERTINO, Calif., Oct. 19 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that Voyager Pharmaceutical has informed DURECT that Voyager is ending its Phase III clinical trials for Memryte(TM) for the treatment of Alzheimer's Disease in order to get an earlier look at
Oct 16, 2006 DURECT Corporation Presenting at BIO InvestorForum 2006
CUPERTINO, Calif., Oct. 16 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present a corporate overview at the BIO InvestorForum 2006 conference. The conference is being held at The Palace Hotel in San Francisco, CA. Dr. James E.
Sep 21, 2006 DURECT Corporation Presenting at the UBS Global Life Sciences Conference
CUPERTINO, Calif., Sept. 21 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the UBS Global Life Sciences Conference. The conference is taking place September 25-28th at The Grand Hyatt Hotel in New York City, New York. Dr. James E.
Sep 12, 2006 DURECT Corporation Appoints Matthew J. Hogan as Chief Financial Officer
CUPERTINO, Calif., Sept. 12 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX), an emerging specialty pharmaceuticals company, announced today that Matthew J. Hogan has joined the Company as Chief Financial Officer. (Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO ) "DURECT is
Aug 04, 2006 DURECT Corporation Presenting at the Securities Research Associates Technology Conference
CUPERTINO, Calif., Aug. 4 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present a corporate overview at the Securities Research Associates Technology Conference on Monday, August 7th at 8:40 a.m. PST. The conference is taking place at the Westin St.
Aug 02, 2006 ORADUR(TM) Technology Milestone: New ORADUR-based Investigational Drug Candidate Commences Phase I Clinical Program
CUPERTINO, Calif., Aug 02, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- DURECT Corporation (Nasdaq: DRRX) reported today the initiation of a Phase I clinical trial for a new ORADUR-based opioid drug candidate. This new drug candidate is the second ORADUR-based opioid drug to undergo
Jul 27, 2006 DURECT Corporation Announces Second Quarter 2006 Financial Results
CUPERTINO, Calif., July 27 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended June 30, 2006. (Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO ) DURECT's net loss for the three months ended June 30, 2006 was $8.7
Jul 19, 2006 DURECT Corporation Invites You to Join its Second Quarter 2006 Conference Call on the Web
CUPERTINO, Calif., July 19 /PRNewswire-FirstCall/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) second quarter 2006 financial results press release, you are invited to listen to its conference call that will be broadcast live over the Internet on Thursday, July 27th, 2006 at 4:30 p.m.
Jul 10, 2006 DURECT Corporation to Present at Upcoming Life Sciences Conferences
CUPERTINO, Calif., July 10 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present a corporate overview at two upcoming life sciences conferences. Leerink Swann & Company/MEDA Corp Pain Roundtable Conference: Monday, July 10, 2006 at the Le Parker Meridien,
Jun 23, 2006 DURECT Corporation Presenting at the Jefferies Life Sciences Conference
CUPERTINO, Calif., June 23 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present a corporate overview at the Jefferies Life Sciences Conference on Tuesday, June 27th at 9:00 a.m. EST. The conference is taking place at The Mandarin Oriental Hotel in New
Jun 12, 2006 DURECT Corporation Presenting at the Needham & Company Fifth Annual Biotechnology and Medical Technology Conference
CUPERTINO, Calif., June 12 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present a corporate overview at the Needham & Company, LLC's Fifth Annual Biotechnology and Medical Technology Conference on Wednesday, June 14th at 8:30 a.m. EST.
May 12, 2006 DURECT Corporation Presenting at the Rodman & Renshaw 3rd Annual Global Healthcare Conference
CUPERTINO, Calif., May 12 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present a corporate overview at the Rodman & Renshaw 3rd Annual Global Healthcare Conference on Tuesday, May 16th at 2:40 p.m. CET. The conference is taking place at Le Meridien Beach
May 05, 2006 ORADUR(TM) Technology Milestone: Remoxy(TM) (ORADUR-Based Oxycodone) Commences Pivotal Phase III Program
CUPERTINO, Calif., May 5 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) reported today that a pivotal Phase III program has been initiated for Remoxy(TM), an abuse-resistant pain medicine under development based on DURECT's patented ORADUR(TM) technology incorporating the opioid
May 02, 2006 DURECT Corporation Announces First Quarter 2006 Financial Results
CUPERTINO, Calif., May 2 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended March 31, 2006. (Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO ) DURECT's net loss for the three months ended March 31, 2006 was $6.3
May 02, 2006 DURECT Corporation Appoints Peter Langecker Chief Medical Officer
CUPERTINO, Calif, May 2 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX), an emerging specialty pharmaceuticals company, announced today that Peter J. Langecker, M.D., Ph.D. has joined the Company as Chief Medical Officer. (Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO)
Apr 27, 2006 DURECT Provides an Update on Its Post-Operative Pain Depot (SABER(TM)-Bupivacaine) Program
CUPERTINO, Calif., April 27 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX), an emerging specialty pharmaceuticals company, provided an update on its post-operative pain relief depot, SABER(TM)-Bupivacaine program. DURECT announced results from its Phase II Australian clinical study in
Apr 25, 2006 DURECT Corporation Invites You to Join Its First Quarter 2006 Conference Call on the Web
CUPERTINO, Calif., April 25, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) first quarter 2006 financial results press release, you are invited to listen to its conference call that will be broadcast live over the Internet on Tuesday,
Apr 19, 2006 DURECT Corporation Presenting at the UBS Global Specialty Pharmaceuticals Conference
CUPERTINO, Calif., April 19 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the UBS Global Specialty Pharmaceuticals Conference. The conference is taking place April 24 - 25th at The Grand Hyatt Hotel in New York City, New York. Schond L.
Mar 30, 2006 DURECT Corporation Presenting at the CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference
CUPERTINO, Calif., March 30 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference. The conference is taking place April 4-5th at The Millennium Broadway Hotel in New York
Feb 17, 2006 ORADUR(TM) Technology Milestone: Remoxy(TM) (ORADUR-based oxycodone) Receives Special Protocol Assessment and Commences Pivotal Phase III
CUPERTINO, Calif., Feb. 17 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) reported today that Remoxy(TM), an abuse-resistant pain medicine under development based on DURECT's patented ORADUR(TM) technology incorporating the opioid oxycodone has successfully completed a Special Protocol
Feb 10, 2006 DURECT Corporation Presenting at the BIO CEO and Investor Conference
CUPERTINO, Calif., Feb. 10 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the BIO CEO Investor Conference. The conference is being held at The Waldorf Hotel in New York, NY. Schond L. Greenway, Vice President, Investor Relations and Strategic
Feb 08, 2006 DURECT Corporation Reports Fourth Quarter and Year End 2005 Financial Results
CUPERTINO, Calif., Feb. 8 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today its financial results for the three months and year ended December 31, 2005. (Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO ) Our net loss for the three months ended December 31, 2005
Feb 08, 2006 DURECT Corporation Announces Anticipated Development Program Milestones for Fiscal Year 2006
CUPERTINO, Calif., Feb. 8 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) today announced its intended development milestones for fiscal year 2006. (Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO ) "These announced milestones are intended to assist the investment community
Jan 26, 2006 DURECT to Expand Clinical Program to Additional Surgical Procedures and to Initiate U.S. Clinical Studies and for its Post-Operative Pain Relief Depot
CUPERTINO, Calif., Jan. 26 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX), an emerging specialty pharmaceutical company, announced today that it plans to expand its worldwide development program for its post-operative pain relief depot, SABER(TM)-Bupivacaine, by initiating additional
Jan 23, 2006 DURECT Corporation Invites You to Join Its Fourth Quarter and Year-End 2005 Conference Call on the Web
CUPERTINO, Calif., Jan. 23 /PRNewswire-FirstCall/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) fourth quarter and year-end 2005 financial results press release, you are invited to listen to its conference call that will be broadcast live over the Internet on Wednesday, February 8th,
Jan 06, 2006 DURECT Announces Promotions and Management Changes
CUPERTINO, Calif., Jan 06, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- DURECT Corporation (Nasdaq: DRRX) announced today the appointment of four executives to its senior management team. Harry Guy has joined DURECT as Vice President of Engineering and Safety.
Jan 03, 2006 DURECT Corporation Presenting at the JPMorgan 24th Annual Healthcare Conference
CUPERTINO, Calif., Jan. 3 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the JPMorgan 24th Annual Healthcare Conference. The conference is being held at The Westin St. Francis Hotel in San Francisco. Dr. James E.
Dec 26, 2005 DURECT Announces Positive Preliminary Results from Transdermal Sufentanil Patch Study in Patients
CUPERTINO, Calif., Dec 26, 2005 /PRNewswire via COMTEX News Network/ -- CUPERTINO, Calif., Dec. 26 /PRNewswire-FirstCall/--DURECT Corporation (Nasdaq: DRRX), an emerging specialty pharmaceuticals company, announced today positive preliminary results from a multiple dose clinical study in chronic
Nov 16, 2005 DURECT Corporation Announces Exercise of Underwriters' Over-Allotment Option
CUPERTINO, Calif., Nov. 15 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that the underwriters of its recent public offering of 7,400,000 shares of its common stock have exercised in full their over-allotment option to purchase an additional 1,110,000 shares of common
Nov 11, 2005 DURECT Highlights Major Commercial Strategic Alliance for ORADUR(TM) Sustained Release Oral Gel-cap Technology
CUPERTINO, Calif., Nov. 11 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced the validation of the commercial potential of its ORADUR(TM) sustained release oral gel-cap technology with the recently announced strategic alliance to develop and commercialize Remoxy(TM), an
Nov 04, 2005 DURECT Corporation Presenting at the Sixteenth Annual CIBC Healthcare Conference
CUPERTINO, Calif., Nov. 4 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the Sixteenth Annual CIBC Healthcare Conference. The conference is being held at The Waldorf-Astoria Hotel in New York, New York. Dr. James E.
Nov 03, 2005 DURECT Corporation Presenting at the Rodman & Renshaw Techvest 7th Annual Healthcare Conference
CUPERTINO, Calif., Nov. 3 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the Rodman & Renshaw Techvest 7th Annual Healthcare Conference. The conference is being held at The Waldorf Astoria in New York, NY. Dr. James E.
Nov 02, 2005 DURECT Corporation Announces Pricing of Public Offering
CUPERTINO, Calif., Nov. 2 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today the pricing of its public offering of 7,400,000 shares of its common stock, including 32,256 shares of common stock offered by certain selling stockholders, at $5.00 per share.
Oct 27, 2005 DURECT Corporation Announces Proposed Public Offering of Common Stock
CUPERTINO, Calif., Oct 27, 2005 /PRNewswire-FirstCall via COMTEX News Network/ -- DURECT Corporation (Nasdaq: DRRX) announced today a proposed offering of 7,400,000 shares of its common stock and 32,256 shares of common stock owned by certain selling stockholders.
Oct 18, 2005 DURECT Announces Positive Preliminary Results From Its Phase II Study for Its Post-Operative Pain Relief Depot
CUPERTINO, Calif., Oct 18, 2005 /PRNewswire-FirstCall via COMTEX News Network/ -- DURECT Corporation (Nasdaq: DRRX) announced today positive preliminary results from the Phase II dose escalation study (Cohorts 1-3) in hernia patients in Australia for DURECT's post-operative pain relief depot,
Oct 14, 2005 DURECT Corporation Announces Initiation of Dosing for Phase III Clinical Program for Memryte (DURIN(TM)-Leuprolide Implant) Program Under Development With Voyager Pharmaceuticals
CUPERTINO, Calif., Oct. 14 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX), an emerging specialty pharmaceutical company announced today the initiation of dosing for the Phase III clinical studies for the DURIN(TM)-based leuprolide program under development with Voyager Pharmaceuticals
Oct 13, 2005 DURECT Corporation Announces Third Quarter 2005 Financial Results
CUPERTINO, Calif., Oct. 13 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended September 30, 2005. DURECT's net loss for the three months ended September 30, 2005 was $3.0 million or 6 cents per share, compared to a net loss of
Oct 07, 2005 DURECT Corporation Invites You to Join Its Third Quarter 2005 Conference Call on the Web
CUPERTINO, Calif., Oct 07, 2005 /PRNewswire-FirstCall via COMTEX News Network/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) third quarter 2005 financial results press release, you are invited to listen to its conference call that will be broadcast live over the Internet on Thursday,
Sep 21, 2005 DURECT to Present Preliminary Phase II Clinical Data for Cohort 3 for Its Post-Operative Pain Relief Depot at American College of Surgeons Conference
CUPERTINO, Calif., Sept 21, 2005 /PRNewswire-FirstCall via COMTEX News Network/ -- DURECT Corporation (Nasdaq: DRRX), an emerging specialty pharmaceutical company, announced today it plans to present preliminary cohort 3 clinical data from its Phase II study for DURECT's post-operative pain relief
Sep 19, 2005 DURECT Corporation Announces Completion of Dosing in Cohort 3 of its Phase II Study for its Post-Operative Pain Relief Depot
CUPERTINO, Calif., Sept. 19 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX - News), an emerging specialty pharmaceutical company, announced today the completion of dosing in the third and final cohort of the Phase II dose escalation study in hernia patients in Australia for DURECT's
Sep 09, 2005 DURECT Corporation Announces Positive Phase III Clinical Results for Remoxy, a Novel Oral Pain Medication using the ORADUR(TM) Gel-Cap
CUPERTINO, Calif., Sept. 9 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX), an emerging specialty pharmaceutical company, announced today that Pain Therapeutics, Inc. has achieved positive Phase III clinical results for Remoxy(TM), a novel long-acting, abuse-deterrent oral formulation
Aug 08, 2005 DURECT Corporation Presenting at Summer Tech Fest 2005 Investor Conference Hosted by C.E. Unterberg Towbin and Security Research Associates
CUPERTINO, Calif., Aug. 8 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the Summer Tech Fest 2005 Investor Conference Hosted by C.E. Unterberg Towbin and Security Research Associates. The conference is being held at the Omni Hotel in San
Aug 01, 2005 DURECT Corporation Presenting at the Adams Harkness & Hill Annual Summer Seminar
CUPERTINO, Calif., Aug. 1 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the Adams, Harkness & Hill Annual Summer Seminar. The conference is being held at the Boston Marriott Long Wharf Hotel. James E.
Jul 22, 2005 DURECT Corporation Announces Second Quarter 2005 Financial Results
CUPERTINO, Calif., July 22 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended June 30, 2005. DURECT's net loss for the three months ended June 30, 2005 was $3.6 million or 7 cents per share, compared to a net loss of $7.4 million
Jul 22, 2005 DURECT Plans to Reduce Convertible Debt Balance by $5 Million
CUPERTINO, Calif., July 22 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that the Company has entered into a privately negotiated agreement with a holder of its 6.25% Convertible Subordinated Notes, due June 2008, to exchange up to $5 million in principal amount of
Jul 12, 2005 DURECT Corporation Presenting at the C. E. Unterberg, Towbin Emerging Growth Conference
CUPERTINO, Calif., July 12 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the C. E. Unterberg, Towbin Emerging Growth Conference. The conference is being held at The Mandarin Oriental Hotel in New York, NY. Dr. James E.
Jul 11, 2005 DURECT Announces Start of Dosing in Cohort 3 of Its Phase II Study for Its Post-Operative Pain Relief Depot
CUPERTINO, Calif., July 11, 2005 /PRNewswire-FirstCall via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today the start of dosing in the third and final cohort of the Phase II dose escalation study in hernia patients in Australia for DURECT's post-operative pain relief depot,
Jul 08, 2005 DURECT Corporation Invites You to Join Its Second Quarter 2005 Conference Call on the Web
CUPERTINO, Calif., July 8, 2005 /PRNewswire-FirstCall via COMTEX/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) second quarter 2005 financial results press release, you are invited to listen to its conference call that will be broadcast live over the Internet on Friday, July 22, 2005
Jun 20, 2005 DURECT Announces Preliminary Results from Cohort 2 of Its On-Going Phase II Study for Its Post-Operative Pain Relief Depot
CUPERTINO, Calif., June 20 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today positive preliminary results from the second cohort of an on-going Phase II clinical study in hernia patients for DURECT's post-operative pain relief depot product candidate,
May 24, 2005 DURECT Corporation Presenting at the Friedman Billings Ramsey 9th Annual Growth Investor Conference
CUPERTINO, Calif., May 24 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the Friedman Billings Ramsey 9th Annual Growth Investor Conference. The conference is taking place June 1-2nd at The Millennium Broadway Hotel in New York City, New York.
May 03, 2005 DURECT Corporation Announces First Quarter 2005 Financial Results and Update on Its Development Programs
CUPERTINO, Calif., May 3 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended March 31, 2005. DURECT's net loss for the three months ended March 31, 2005 was $5.4 million or 10 cents per share, compared to a net loss of $6.0
Apr 19, 2005 DURECT Corporation Invites You to Join Its First Quarter 2005 Conference Call on the Web
CUPERTINO, Calif., April 19 /PRNewswire-FirstCall/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) first quarter 2005 financial results press release, you are invited to listen to its conference call that will be broadcast live over the Internet on Tuesday, May 3, 2005 at 4:30 p.m. EDT.
Apr 18, 2005 Simon X. Benito Appointed to the Board of Directors of DURECT Corporation to Replace Albert L. Zesiger
CUPERTINO, Calif., April 18, 2005 /PRNewswire-FirstCall via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today that effective April 14, 2005, the company has appointed Simon X. Benito to its Board of Directors to replace Albert L. Zesiger who is stepping down as a member of the Board of
Apr 11, 2005 DURECT Corporation Announces Planned Departure of CFO and Director Thomas A. Schreck
CUPERTINO, Calif., April 11 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today the expected departure of Thomas A. Schreck, Co-Founder and Chief Financial Officer on April 30, 2005, to pursue other interests in private ventures in the life sciences sector. Mr.
Mar 29, 2005 DURECT Corporation Presenting at the CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference
CUPERTINO, Calif., March 29, 2005 /PRNewswire-FirstCall via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference. The conference is taking place April 4-5th at The Millennium Broadway
Mar 14, 2005 DURECT Corporation and Endo Pharmaceuticals Sign Agreement to Develop and Commercialize DURECT'S Seven-Day Transdermal Pain Patch
CUPERTINO, Calif., March 14, 2005 /PRNewswire-FirstCall via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it has signed an agreement with Endo Pharmaceuticals Inc., a wholly owned subsidiary of Endo Pharmaceuticals Holdings Inc. (Nasdaq: ENDP), that will give Endo the exclusive
Feb 24, 2005 DURECT Corporation to Present at the Security Research Associates' Spring Technology & Life Sciences Investor Conference
CUPERTINO, Calif., Feb 24, 2005 /PRNewswire-FirstCall via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the Security Research Associates Spring Technology & Life Sciences Investor Conference at the Campton Place Hotel in San Francisco. Dr. James E.
Feb 16, 2005 DURECT Initiates Phase II Program for Its Sufentanil Patch Product
CUPERTINO, Calif., Feb. 16 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX), an emerging specialty pharmaceuticals systems company, today announced the initiation of the Phase II program for DURECT's TRANSDUR(TM)-based sufentanil patch. Based on the results of our Phase I trial for our
Feb 10, 2005 DURECT Corporation Reports Fourth Quarter and Year End 2004 Financial Results
CUPERTINO, Calif., Feb 10, 2005 /PRNewswire-FirstCall via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today its financial results for the three months and year ended December 31, 2004. (Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO ) Our net loss for the three months ended
Feb 10, 2005 DURECT Completes Dosing of the Phase I Pharmacokinetic Study for Its Sufentanil Patch Product and of the First Cohort of the Phase II Study for Its Post-Operative Pain Relief Depot
CUPERTINO, Calif., Feb. 10 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX), an emerging specialty pharmaceuticals systems company, today announced the completion of dosing of the Phase I pharmacokinetic study for DURECT's TRANSDUR(TM)-based sufentanil patch.
Jan 28, 2005 DURECT Corporation Announces Completion of Clinical Trial Enrollment for DURIN(TM)-Based Leuprolide Product Candidate
CUPERTINO, Calif., and RALEIGH, N.C., Jan 28, 2005 /PRNewswire-FirstCall via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX), an emerging specialty pharmaceutical systems company, and Voyager Pharmaceutical Corporation, a privately held specialty pharmaceutical company focused on diseases of aging,
Jan 25, 2005 DURECT Names Dr. Paula Mendenhall Senior Vice President of Operations
CUPERTINO, Calif., Jan. 25 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that Dr. Paula Mendenhall has joined DURECT as Senior Vice President of Operations. Dr. Mendenhall has over 30 years of pharmaceutical experience covering areas such as research, manufacturing and
Jan 20, 2005 DURECT Corporation Invites You to Join its Fourth Quarter and Year-End 2004 Conference Call on the Web
CUPERTINO, Calif., Jan. 20 /PRNewswire-FirstCall/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) fourth quarter and year-end 2004 financial results press release, you are invited to listen to its conference call that will be broadcast live over the Internet on Thursday, February 10,
Jan 12, 2005 DURECT Corporation Announces Development Program Milestones for Fiscal Year 2005
CUPERTINO, Calif., Jan. 12 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) today announced its intended clinical and corporate milestones for the fiscal year 2005. "These announced milestones are intended to assist the investment community to track our progress throughout the coming
Jan 05, 2005 DURECT Corporation Presents an Update to Its Development Pipeline and Hosts 1st Analyst Luncheon
CUPERTINO, Calif., Jan. 5 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that the Company will host a reception to provide an update to its development pipeline and program objectives for fiscal year 2005. The presentation will be held at the Weinstein Gallery in San
Dec 23, 2004 DURECT Corporation Announces Initiation of Phase III Studies for Remoxy, a Novel Oral Pain Medication using the ORADUR(TM) Gel-Cap
CUPERTINO, Calif., Dec. 23 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX), an emerging specialty pharmaceutical systems company, announced today the initiation of Phase III clinical testing for Remoxy(TM), a novel long-acting, abuse-deterrent oral formulation of oxycodone based on
Dec 20, 2004 DURECT and Voyager Pharmaceutical Announce the Acceptance of DURIN(TM) Investigational New Drug Application and Clinical Protocol by the FDA for the Treatment of Alzheimer's Disease
CUPERTINO, Calif., Dec. 20 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX), an emerging specialty pharmaceutical systems company, and Voyager Pharmaceutical Corporation, a privately held specialty pharmaceutical company focused on diseases of aging, announced today the acceptance of the
Nov 22, 2004 DURECT Corporation Presenting at the Lazard 1st Annual Life Sciences Conference
CUPERTINO, Calif., Nov 22, 2004 /PRNewswire-FirstCall via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the Lazard First Annual Life Sciences Conference. The conference is being held at Mandarin Oriental Hotel in New York, New York. Dr.
Nov 04, 2004 DURECT Corporation Presenting at the Fifteenth Annual CIBC Healthcare Conference
CUPERTINO, Calif., Nov 4, 2004 (PRNewswire-FirstCall via COMTEX) -- DURECT Corporation announced today that it will present at the Fifteenth Annual CIBC Healthcare Conference. The conference is being held at The Plaza Hotel in New York, New York. Dr. James E.
Oct 25, 2004 DURECT Corporation Announces Third Quarter 2004 Financial Results and Update on Its Development Programs
CUPERTINO, Calif., Oct. 25 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended September 30, 2004 and an update on its development programs. (Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO ) Our net loss for the three
Oct 25, 2004 DURECT Initiates Phase II Clinical Program for Post-Operative Pain Relief Depot
CUPERTINO, Calif., Oct. 25 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today the initiation of a Phase II clinical study for its post-operative pain relief depot (SABER-bupivacaine), a sustained-release formulation of a local anesthetic using the Company's SABER(TM) drug
Oct 22, 2004 DURECT Initiates Phase I Trial for Its Proprietary Transdermal Sufentanil Patch
Patch to be Highlighted at ASA 2004 Annual Meeting CUPERTINO, Calif., Oct. 22 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) today announced the initiation of a phase I clinical trial for a new proprietary transdermal sufentanil product. The trial consists of a pharmacokinetic study in
Oct 22, 2004 DURECT Corporation Presenting at the C. E. Unterberg, Towbin Specialty Pharmaceutical Conference
CUPERTINO, Calif., Oct 22, 2004 /PRNewswire-FirstCall via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the C. E. Unterberg, Towbin Specialty Pharmaceutical Conference. The conference is being held at The Palace Hotel in New York, NY. Dr. James E.
Oct 21, 2004 DURECT Corporation Presenting at the Rodman & Renshaw Techvest 6th Annual Healthcare Conference
CUPERTINO, Calif., Oct. 21 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the Rodman & Renshaw Techvest 6th Annual Healthcare Conference. The conference is being held at The Waldorf Astoria in New York, NY. Dr. James E.
Oct 18, 2004 DURECT Corporation Invites You to Join its Third Quarter 2004 Conference Call on the Web
CUPERTINO, Calif., Oct. 18 /PRNewswire-FirstCall/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) third quarter 2004 financial results press release, you are invited to listen to its conference call that will be broadcast live over the Internet on Monday, October 25, 2004 at 4:30 p.m.
Oct 12, 2004 DURECT Corporation Presenting at the HealthpointCapital Biomaterials Summit
CUPERTINO, Calif., Oct. 12 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the HealthpointCapital Biomaterials Summit. The conference is being held at the Omni Berkshire Place in New York City, NY. Thomas A.
Oct 05, 2004 DURECT Corporation Presenting at BIO Emerging Company Investor Forum
CUPERTINO, Calif., Oct. 5 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the BIO Emerging Company Investor Forum. The conference is being held at The Palace Hotel in San Francisco, CA. Dr. Felix Theeuwes, Chairman and Chief Scientific Officer,
Sep 16, 2004 DURECT Corporation Presenting at the First Annual Merriman Curhan Ford & Co. Investor Summit
CUPERTINO, Calif., Sep 16, 2004 /PRNewswire-FirstCall via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the First Annual Merriman Curhan Ford & Co. Investor Summit. The conference is being held at The Mark Hopkins Hotel in San Francisco, CA. Dr. James E.
Aug 09, 2004 DURECT Corporation Presenting at the Halpern Capital Summer Growth Stock Conference
CUPERTINO, Calif., Aug. 9 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the Halpern Capital Summer Growth Stock Conference. The conference is being held at The Campton Place Hotel in San Francisco, CA. Dr.
Aug 02, 2004 DURECT Corporation Presenting at the Adams Harkness & Hill's 24th Summer Seminar
CUPERTINO, Calif., Aug 2, 2004 /PRNewswire-FirstCall via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the Adams, Harkness & Hill - 24th Annual Summer Seminar. The conference is being held at the Boston Marriott Long Wharf Hotel. Thomas A.
Jul 21, 2004 DURECT Corporation Announces Second Quarter 2004 Financial Results and Update on Its Development Programs
CUPERTINO, Calif., July 21 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended June 30, 2004 and an update on its development programs. Our net loss for the three months ended June 30, 2004 was $7.4 million or 14 cents per share,
Jul 15, 2004 DURECT Corporation Invites You to Join Its Second Quarter 2004 Conference Call on the Web
CUPERTINO, Calif., July 15 /PRNewswire-FirstCall/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) second quarter 2004 financial results press release, you are invited to listen to its conference call that will be broadcast live over the Internet on Wednesday, July 21, 2004 at 4:30 p.m.
Jul 06, 2004 DURECT Announces Positive Clinical Results With Its ORADUR(TM) Sustained Release Oral Gel-Cap Technology
CUPERTINO, Calif., July 6 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced the advancement of its ORADUR(TM) sustained release oral gel-cap technology (formerly referred to as the SABER(TM) oral gel-cap technology) with positive human clinical results for Remoxy(TM).
Jun 21, 2004 DURECT Corporation and NeuroSystec Corporation Announce Exclusive Agreement to Develop Treatments for Certain Inner Ear Disorders Including Tinnitus
CUPERTINO, Calif., and VALENCIA, Calif., June 21 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) and NeuroSystec Corporation ("NeuroSystec"), a privately held company located in Valencia, CA, announced today that they have signed an exclusive agreement to develop, market and sell
May 06, 2004 DURECT Corporation Presenting at the Rodman & Renshaw Healthcare Conference
CUPERTINO, Calif., May 6 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the Rodman & Renshaw Techvest Global Healthcare Conference at 3:30 PM local time (10:30 AM, Eastern Daylight Time) on Wednesday, May 12, 2004 in London, England.
Apr 27, 2004 DURECT Corporation Presenting at the CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference
CUPERTINO, Calif., April 27 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference. The conference is taking place April 27-28th at The Millennium Broadway Hotel in New
Apr 22, 2004 DURECT Corporation Announces First Quarter 2004 Financial Results
CUPERTINO, Calif., April 22 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended March 31, 2004. (Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO ) DURECT's net loss for the three months ended March 31, 2004 was $6.0
Apr 14, 2004 DURECT Corporation Invites You to Join Its First Quarter 2004 Conference Call on the Web
CUPERTINO, Calif., Apr 14, 2004 /PRNewswire-FirstCall via COMTEX/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) first quarter 2004 financial results press release, you are invited to listen to its conference call that will be broadcast live over the Internet on Thursday, April 22, 2004
Mar 23, 2004 Michael D. Casey Appointed to the Board of Directors of DURECT Corporation
CUPERTINO, Calif., Mar 23, 2004 /PRNewswire-FirstCall via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today the appointment of Michael D. Casey to its Board of Directors to replace John L. Doyle who left the Board in November 2003. The appointment of Mr.
Feb 24, 2004 DURECT Corporation Presenting at the 4th Annual Smith Barney Citigroup Specialty Pharmaceuticals Conference
CUPERTINO, Calif., Feb. 24 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the Smith Barney Citigroup Specialty Pharmaceuticals Conference. The conference is taking place February 24-25th at The Marriott East Side Hotel in New York City, New York.
Feb 13, 2004 DURECT Announces Promotions and Management Changes
CUPERTINO, Calif., Feb. 13 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that Dr. Su IL Yum has been promoted to Senior Vice President of Engineering. (Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO ) "We are very fortunate to have Su IL to help us through
Feb 10, 2004 DURECT Corporation Reports Fourth Quarter 2003 and Year End Financial Results
CUPERTINO, Calif., Feb. 10 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today its financial results for the three months and year ended December 31, 2003. (Photo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO ) DURECT's net loss for the three months ended December
Jan 27, 2004 DURECT Corporation Invites You to Join Its Fourth Quarter and Year End 2003 Conference Call on the Web
CUPERTINO, Calif., Jan. 27 /PRNewswire-FirstCall/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) fourth quarter and year end 2003 financial results press release, you are invited to listen to its conference call that will be broadcast live over the Internet on Tuesday, February 10, 2004
Jan 06, 2004 DURECT Corporation Presenting at the JPMorgan H&Q 22nd Annual Healthcare Conference
CUPERTINO, Calif., Jan. 6 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the JPMorgan H&Q 22nd Annual Healthcare Conference. The conference is taking place January 12-15th at The Westin St. Francis Hotel in San Francisco. Dr. James E.
Nov 07, 2003 DURECT Corporation Presenting at The CIBC World Markets 14th Annual Healthcare Conference
CUPERTINO, Calif., Nov. 7 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the CIBC Annual Biotechnology and Specialty Pharmaceuticals Conference. The conference is being held at The Plaza Hotel in New York City. James E.
Nov 06, 2003 DURECT Corporation Announces Third Quarter 2003 Financial Results
CUPERTINO, Calif., Nov. 6 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today its financial results for the three months ended September 30, 2003. (Photo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO ) DURECT's net loss for the three months ended September 30, 2003
Nov 06, 2003 DURECT Announces Positive Clinical Results for its Post-operative Pain Relief Depot using the SABER(TM) Delivery System
CUPERTINO, Calif., Nov. 6 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that the Company has completed its first study in humans with its post-operative pain relief depot product. DURECT's post-operative pain relief depot product, a sustained release injectable using
Oct 20, 2003 DURECT Corporation Invites You to Join Its Third Quarter 2003 Conference Call On the Web
CUPERTINO, Calif., Oct. 20 /PRNewswire-FirstCall/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) third quarter 2003 financial results press release, you are invited to listen to its conference call that will be broadcast live over the Internet on Thursday, November 6, 2003 at 4:30 p.m.
Oct 17, 2003 DURECT Announces Update to CHRONOGESIC Program
CUPERTINO, Calif., Oct. 16 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it has received data from a preclinical animal test with its CHRONOGESIC(R) (sufentanil) Pain Therapy Product which indicate that a small number of units (less than 2% in total) utilizing the
Oct 09, 2003 DURECT Initiates Manufacture of Clinical Product for its CHRONOGESIC(R) (Sufentanil) Pain Therapy Product
CUPERTINO, Calif., Oct 9, 2003 /PRNewswire-FirstCall via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it has initiated manufacture of clinical product for its anticipated pharmacokinetic study and other initial clinical studies in the Phase III program for its CHRONOGESIC(R)
Sep 23, 2003 Jon S. Saxe Appointed to the Board of Directors of DURECT Corporation
CUPERTINO, Calif., Sept. 23 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that the company has appointed Jon S. Saxe to its Board of Directors to replace James R. Butler who stepped down as a member of the Board of Directors in June 2003. Mr.
Sep 03, 2003 DURECT Corporation Presenting at the Thomas Weisel Partners Healthcare Conference
CUPERTINO, Calif., Sep 3, 2003 /PRNewswire-FirstCall via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the Thomas Weisel Partners Annual Healthcare Conference. The conference is being held at the Four Seasons Hotel in Boston, MA. James E.
Sep 02, 2003 DURECT Corporation Completes Validation of Terminal Sterilization Manufacturing Process for its CHRONOGESIC (sufentanil) Pain Therapy Product
CUPERTINO, Calif., Sep 2, 2003 /PRNewswire-FirstCall via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it has completed validation of the terminal sterilization manufacturing process for its CHRONOGESIC (sufentanil) Pain Therapy product.
Aug 05, 2003 DURECT Corporation Presenting at the Adams Harkness & Hill's 23rd Summer Seminar
CUPERTINO, Calif., Aug. 5 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the Adams, Harkness & Hill -- 23rd Annual Summer Seminar. The conference is being held at the Boston Marriott Long Wharf Hotel. James E.
Jul 24, 2003 DURECT Corporation Announces Second Quarter 2003 Financial Results
CUPERTINO, Calif., Jul 24, 2003 /PRNewswire-FirstCall via Comtex/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended June 30, 2003. (Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO ) DURECT's net loss for the three months ended June 30,
Jul 11, 2003 Initial Purchaser Exercises Option to Purchase an Additional $10 Million Of the $50 Million of 6.25% Convertible Notes
CUPERTINO, Calif., Jul 11, 2003 /PRNewswire-FirstCall via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today that the initial purchaser of $50 million of its 6.25% Convertible Notes due 2008 has elected to exercise its option to purchase an additional $10 million principal amount of such
Jul 11, 2003 DURECT Corporation Invites You to Join its Second Quarter 2003 Conference Call on the Web
CUPERTINO, Calif., July 11 /PRNewswire-FirstCall/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) second quarter 2003 financial results press release, you are invited to listen to its conference call that will be broadcast live over the Internet on Thursday, July 24, 2003 at 4:30 p.m.
Jun 13, 2003 DURECT Corporation Announces Pricing of $50 Million Convertible Note Offering
CUPERTINO, Calif., June 13 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it agreed to privately place $50 million aggregate principal amount of Convertible Notes due 2008. These Notes will be convertible into DURECT Corporation common stock at a conversion price
Jun 11, 2003 DURECT Corporation Announces Proposed $50 Million Convertible Debt Offering
CUPERTINO, Calif., June 11 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it proposes to offer a new issue of $50 million of Convertible Notes due 2008 through a Rule 144A offering to qualified institutional buyers. These notes will be convertible into DURECT
Jun 10, 2003 DURECT Initiates Human Clinical Testing for Its Post-operative Pain Relief Depot Using the SABER(TM) Delivery System
CUPERTINO, Calif., June 10 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that the Company has commenced clinical testing of its post-operative pain relief depot product. DURECT's post-operative pain relief depot product, a sustained release injectible using the
May 15, 2003 DURECT Corporation Presenting at Friedman Billings Ramsey 7th Annual Technology & Growth Investor Conference
CUPERTINO, Calif., May 15, 2003 /PRNewswire-FirstCall via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the Friedman Billings Ramsey 7th Annual Technology & Growth Investor Conference. The conference is being held at The Millennium Hotel in New York City.
Apr 28, 2003 DURECT Corporation Announces First Quarter 2003 Financial Results
CUPERTINO, Calif., April 28 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended March 31, 2003. DURECT's net loss for the three months ended March 31, 2003 was $5.9 million or 12 cents per share, compared to $9.7 million or 20
Apr 28, 2003 DURECT Corporation Presenting at The CIBC World Markets Annual Biotechnology And Specialty Pharmaceuticals Conference
CUPERTINO, Calif., April 28 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the CIBC Annual Biotechnology and Specialty Pharmaceuticals Conference. The conference is being held at The Millennium Hotel in New York City. James E.
Apr 15, 2003 DURECT Corporation Invites You to Join Its First Quarter 2003 Conference Call on the Web
CUPERTINO, Calif., April 15 /PRNewswire-FirstCall/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) first quarter 2003 financial results press release, you are invited to listen to its conference call that will be broadcast live over the Internet on Monday, April 28, 2003 at 4:30 p.m.
Jan 28, 2003 DURECT Corporation Reports Fourth Quarter 2002 and Year End Financial Results
CUPERTINO, Calif., Jan. 28 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months and year ended December 31, 2002. DURECT's net loss for the three months ended December 31, 2002 was $8.5 million or 17 cents per share, compared to $10.1
Jan 15, 2003 DURECT Corporation Invites You to Join Its Fourth Quarter And Year End 2002 Conference Call on the Web
CUPERTINO, Calif., Jan. 15 /PRNewswire-FirstCall/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) fourth quarter and year end 2002 financial results press release, you are invited to listen to its conference call that will be broadcast live over the Internet on Tuesday, January 28, 2003
Jan 14, 2003 Pain Therapeutics and DURECT Corporation Announce Exclusive Agreement to Formulate Certain Long-Acting Opioid Drugs
SOUTH SAN FRANCISCO, Calif. and CUPERTINO, Calif., Jan. 14 /PRNewswire- FirstCall/ -- Pain Therapeutics, Inc. (Nasdaq: PTIE) and DURECT Corporation (Nasdaq: DRRX) today announced they have signed an exclusive licensing agreement to formulate certain long-acting opioid drugs.
Jan 02, 2003 DURECT Corporation Presenting at the JPMorgan H&Q 21st Annual Healthcare Conference
CUPERTINO, Calif., Jan. 2 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the JPMorgan H&Q 21st Annual Healthcare Conference. The conference is taking place January 6-9th at The Westin St. Francis Hotel in San Francisco. Dr. James E.
Dec 27, 2002 David R. Hoffmann Appointed to the Board of Directors of DURECT Corporation
CUPERTINO, Calif., Dec. 27 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that the company has appointed David R. Hoffmann to its Board of Directors to replace Matthew V. McPherron who is stepping down as a member of the Board of Directors.
Nov 22, 2002 DURECT Corporation Increases Focus on Product Development Activities and Reducing Costs
CUPERTINO, Calif., Nov. 22 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it is reducing operating expenses in accordance with the Company's overall corporate objectives for the fiscal year 2003. DURECT's long-term strategy and business plan remain on track.
Nov 19, 2002 BioPartners and DURECT Corporation Enter Into Agreement for Development Of Sustained Release Interferon Alpha
ZUG, Switzerland and CUPERTINO, Calif., Nov. 19 /PRNewswire-FirstCall/ -- BioPartners, a global biopharmaceuticals company and one of the leaders in the emerging field of competitively priced multi-source biopharmaceuticals, has signed an exclusive agreement with DURECT Corporation (Nasdaq: DRRX),
Nov 14, 2002 DURECT Corporation and Thorn BioScience LLC Expand Existing Licensing Agreement to Develop Veterinary Products
CUPERTINO, Calif., Nov. 14 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) and Thorn BioScience LLC announced today that the two companies have expanded their agreement for the development and commercialization of veterinary products for reproductive indications using DURECT's SABER(TM)
Nov 12, 2002 DURECT Corporation Reports Third Quarter 2002 Financial Results
CUPERTINO, Calif., Nov. 12 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended September 30, 2002. (Photo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO ) DURECT's net loss for the three months ended September 30, 2002 was
Nov 12, 2002 DURECT Corporation and ALZA Corporation Amend Licensing Agreement
CUPERTINO, Calif., Nov. 12 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it has amended its development and commercialization agreement with ALZA Corporation under which DURECT holds exclusive rights to develop, commercialize and manufacture products using ALZA's
Nov 11, 2002 DURECT Corporation Postpones Its Third Quarter 2002 Conference Call
CUPERTINO, Calif., Nov. 11 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will postpone its third quarter financial results press release and conference call to Tuesday, November 12th, 2002. The earnings release is postponed due to the announcement today by
Nov 11, 2002 Endo Pharmaceuticals and DURECT Corporation Agree To Collaborate on Treatment in Pain Management
CHADDS FORD, Pa. and CUPERTINO, Calif., Nov. 11 /PRNewswire-FirstCall/ -- Endo Pharmaceuticals Holdings Inc. (Nasdaq: ENDP) and DURECT Corporation (Nasdaq: DRRX), announced today that they have signed an agreement to collaborate on the development and commercialization of DURECT's CHRONOGESIC(TM)
Oct 30, 2002 DURECT Corporation Presenting at The CIBC World Markets 13th Annual Health Care Conference
CUPERTINO, Calif., Oct 30, 2002 /PRNewswire-FirstCall via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the CIBC World Markets 13th Annual Health Care Conference. The conference is being held at The Plaza Hotel in New York City. Dr. James E.
Oct 16, 2002 DURECT Corporation Invites You to Join Its Third Quarter 2002 Conference Call on the Web
CUPERTINO, Calif., Oct 16, 2002 /PRNewswire-FirstCall via COMTEX/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) third quarter financial results press release, you are invited to listen to its conference call that will be broadcast live over the Internet on Monday, November 11th, 2002
Oct 04, 2002 DURECT Corporation Presenting at The UBS Warburg Global Life Sciences Conference
CUPERTINO, Calif., Oct 4, 2002 /PRNewswire-FirstCall via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the UBS Warburg Global Life Sciences Conference. The conference is being held at The Plaza Hotel in New York City. Thomas A.
Aug 26, 2002 DURECT Corporation Delays Enrolling Additional Patients in Its Phase III Clinical Trial for CHRONOGESIC Pending Clinical Trial Protocol Amendments
CUPERTINO, Calif., Aug 26, 2002 /PRNewswire-FirstCall via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today that, following discussions between DURECT and the FDA on DURECT's on-going Phase III clinical trial for the CHRONOGESIC(TM) (sufentanil) Pain Therapy System, the FDA has requested
Aug 05, 2002 DURECT Corporation Presenting at The Adams, Harkness & Hill's 22nd Annual Summer Seminar
CUPERTINO, Calif., Aug 5, 2002 /PRNewswire-FirstCall via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the Adams, Harkness & Hill - 22nd Annual Summer Seminar. The conference is being held at The Boston Marriott Long Wharf Hotel. Dr. James E.
Jul 29, 2002 DURECT Corporation Reports Second Quarter 2002 Financial Results
CUPERTINO, Calif., Jul 29, 2002 /PRNewswire-FirstCall via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended June 30, 2002. (Photo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO ) DURECT's net loss for the three months ended June 30,
Jul 29, 2002 DURECT Corporation and Voyager Pharmaceutical Corporation Sign Development and Commercialization Agreement to Develop Treatment for Alzheimer's Disease
CUPERTINO, Calif., Jul 29, 2002 /PRNewswire-FirstCall via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) and Voyager Pharmaceutical Corporation announced today that the two companies have signed a development and commercialization agreement to develop Voyager's patented product, using leuprolide
Jul 09, 2002 DURECT Initiates Pivotal Phase III Program for the CHRONOGESIC(TM) (Sufentanil) Pain Therapy System
CUPERTINO, Calif., Jul 9, 2002 /PRNewswire-FirstCall via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it has begun dosing of patients in the first clinical trial of its pivotal Phase III program for the CHRONOGESIC(TM) (sufentanil) Pain Therapy System.
Jul 08, 2002 DURECT Corporation Invites You to Join Its Second Quarter 2002 Conference Call on the Web
CUPERTINO, Calif., Jul 8, 2002 /PRNewswire-FirstCall via COMTEX/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) second quarter financial results press release, you are invited to listen to its conference call that will be broadcast live over the Internet on Monday, July 29, 2002 at 4:30
Jun 11, 2002 DURECT Corporation to Present at the Goldman Sachs Twenty - Third Annual Global Healthcare Conference
CUPERTINO, Calif., Jun 11, 2002 /PRNewswire-FirstCall via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the Goldman Sachs Twenty - Third Annual Global Healthcare Conference. The conference is being held at The Ritz - Carlton, Laguna Niguel in California. Dr.
Jun 05, 2002 DURECT Corporation Presenting at the UBS Warburg Global Specialty Pharmaceuticals Conference
CUPERTINO, Calif., Jun 5, 2002 /PRNewswire-FirstCall via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the UBS Warburg Global Specialty Pharmaceuticals Conference. The conference is taking place June 5-6, 2002 at the Grand Hyatt New York. Thomas A.
Apr 29, 2002 DURECT Corporation Presenting at the CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference
CUPERTINO, Calif., Apr 29, 2002 /PRNewswire-FirstCall via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference. The conference is taking place May 1-2, 2002 at The Millennium Hotel in
Apr 24, 2002 DURECT Corporation Reports First Quarter 2002 Financial Results
CUPERTINO, Calif., Apr 24, 2002 /PRNewswire-FirstCall via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended March 31, 2002. DURECT's net loss for the three months ended March 31, 2002 was $9.7 million or 20 cents per share, compared to $4.9
Apr 08, 2002 DURECT Corporation Invites You to Join its First Quarter 2002 Conference Call on the Web
CUPERTINO, Calif., Apr 8, 2002 (BUSINESS WIRE) -- In conjunction with DURECT Corporation's (Nasdaq:DRRX) first quarter financial results press release, you are invited to listen to its conference call that will be broadcast live over the Internet on Wednesday, April 24, 2002 at 4:30 p.m.
Apr 02, 2002 DURECT Corporation Files IND for the Long Term Treatment of Asthma
CUPERTINO, Calif., Apr 2, 2002 /PRNewswire-FirstCall via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it has filed an Investigational New Drug application to investigate the delivery of cromolyn sodium for the treatment of asthma.
Mar 27, 2002 DURECT Corporation and Cardinal Health Announce Collaboration to Research And Develop Long Acting Gel-Cap Products Using the SABER(TM) Delivery System
CUPERTINO, Calif., Mar 27, 2002 /PRNewswire-FirstCall via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today a collaboration with Cardinal Health (NYSE: CAH) Pharmaceutical Technologies and Services Center, Inc. to explore the feasibility of producing long acting soft gelatin based oral
Mar 18, 2002 DURECT Corporation Announces Positive Results of Pilot Phase III Study For The CHRONOGESIC(TM) Product
CUPERTINO, Calif., Mar 18, 2002 /PRNewswire-FirstCall via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today the results from a pilot Phase III clinical study for its lead product in development, the CHRONOGESIC(TM) (sufentanil) Pain Therapy System for the treatment of chronic pain.
Jan 30, 2002 DURECT Corporation Reports Fourth Quarter 2001 and Year End Financial Results
CUPERTINO, Calif., Jan. 30 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months and year ended December 31, 2001. The Company's net loss attributable to common stockholders for the three months ended December 31, 2001 was $10.1 million
Jan 23, 2002 DURECT Corporation Sponsors Symposium on Novel Drug Delivery Technologies at the 45th Annual Meeting of the Western Pharmacology Society (WPS)
CUPERTINO, Calif., Jan. 23 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it is sponsoring a symposium on novel drug delivery technologies at the 45th Annual Meeting of the Western Pharmacology Society (WPS) being held at the Hotel El Cid in Mazatlan, Sinaloa,
Jan 15, 2002 DURECT Corporation Invites You to Join its Fourth Quarter and Year End 2001 Conference Call on the Web
CUPERTINO, Calif., Jan 14, 2002 (BUSINESS WIRE) -- In conjunction with DURECT Corporation's (NASDAQ:DRRX) fourth quarter and year end 2001 financial results press release, you are invited to listen to its conference call that will be broadcast live over the Internet on Wednesday, January 30, 2002
Jan 04, 2002 DURECT Corporation Presenting at the JPMorgan H&Q 20th Annual Healthcare Conference
CUPERTINO, Calif., Jan 4, 2002 /PRNewswire via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the JPMorgan H&Q 20th Annual Healthcare Conference. The conference is taking place January 7-10th at The Westin St. Francis Hotel in San Francisco. James E.
Nov 16, 2001 Janssen Pharmaceutica Enters Into Exclusive Marketing Discussions With DURECT Corporation for Chronogesic(TM)
CUPERTINO, Calif., Nov 16, 2001 /PRNewswire via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today that ALZA Corporation has exercised its option to allow ALZA and Janssen Pharmaceutica Products, L.P., the right to begin negotiations for exclusive sales and marketing rights to DURECT's
Nov 01, 2001 DURECT Corporation Presenting at the CIBC World Markets Twelfth Annual Health Care Conference
CUPERTINO, Calif., Nov. 1 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the CIBC World Markets Twelfth Annual Health Care Conference. The conference is taking place November 5-7 at The Plaza in New York City. Thomas A.
Nov 01, 2001 DURECT Corporation Reports Initiation of Phase III Program for Chronogesic(TM
CUPERTINO, Calif., Nov. 1 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced during its third quarter financial results conference call yesterday that the company has commenced its Phase III program for Chronogesic(TM), for the treatment of chronic pain.
Oct 31, 2001 DURECT Corporation Reports Third Quarter 2001 Financial Results
CUPERTINO, Calif., Oct. 31 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended September 30, 2001. The company's net loss attributable to common stockholders for the three months ended September 30, 2001 was $8.9 million or 19 cents per
Oct 25, 2001 DURECT Announces Results From Research Collaboration With the University of Maastricht Showing Blood Flow to the Ischemic Heart Restored Following Local Administration of Growth Factors
CUPERTINO, Calif., Oct 25, 2001 /PRNewswire via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced yesterday research results showing in animal models that new blood vessels are formed and that blood flow to an ischemic heart can be restored following targeted delivery of fibroblast growth
Oct 16, 2001 DURECT Corporation Presenting at the Techvest 3rd Annual Healthcare Conference
CUPERTINO, Calif., Oct 16, 2001 /PRNewswire via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present on technologies for targeted drug delivery at the Techvest 3rd Annual Conference on Tissue Repair, Replacement and Regeneration (TR3).
Oct 15, 2001 DURECT Corporation Invites You to Join its Third Quarter 2001 Conference Call on the Web
CUPERTINO, Calif., Oct 15, 2001 /PRNewswire via COMTEX/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) third quarter financial results press release, you are invited to listen to its conference call that will be broadcast live over the Internet on Wednesday, October 31, 2001 at 4:30
Sep 24, 2001 DURECT Corporation Announces Promotions of Officers
CUPERTINO, Calif., Sept. 24 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that Judy Magruder has been promoted to the position of Senior Vice President of Regulatory and Development and Tai Wah Chan, Ph.D. has been promoted to Vice President of Pharmaceutical Research and
Sep 05, 2001 DURECT Announces Positive Phase II Results on Chronogesic(TM) For Long-Term Pain Relief
CUPERTINO, Calif., Sept. 5 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today the results of its Phase II clinical trial for its lead product Chronogesic(TM), a 3-month continuous infusion subcutaneous implant for the treatment of chronic pain.
Aug 24, 2001 DURECT Corporation Invites You to Join Its Phase II Trial Results Conference Call on the Web
CUPERTINO, Calif., Aug 24, 2001 /PRNewswire/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) press release regarding Chronogesic(TM) Phase II clinical trial data, you are invited to listen to its conference call that will be broadcast live over the Internet on Wednesday, September 5,
Jul 30, 2001 DURECT Corporation Reports Second Quarter 2001 Financial Results
CUPERTINO, Calif., July 30 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended June 30, 2001. The company's net loss attributable to common stockholders for the three months ended June 30, 2001 was $7.0 million or 15 cents per share
Jul 19, 2001 DURECT Corporation Invites You to Join its Second Quarter 2001 Conference Call on the Web
CUPERTINO, Calif., Jul 19, 2001 /PRNewswire/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) second quarter financial results press release, you are invited to listen to its conference call that will be broadcast live over the Internet on Monday, July 30, 2001 at 4:30 p.m.
Jul 06, 2001 Durect Corporation Adopts Stockholder Rights Plan
CUPERTINO, Calif., Jul 6, 2001 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that its Board of Directors adopted a Stockholder Rights Plan. The Rights Plan is designed to protect and maximize the value of stockholders' interest in DURECT Corporation, to enable all DURECT
Jun 29, 2001 DURECT Announces Chronogesic Preliminary Clinical Results of Phase II Trial
CUPERTINO, Calif., June 29 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today the preliminary results of its Phase II clinical trial for its lead product, a 3-month continuous infusion subcutaneous implant for the treatment of chronic pain.
Jun 25, 2001 DURECT Announces Filing of Special 510(k) Application for its New Generation IntraEAR(R) Ear Catheter Product and Approval of Physician Sponsored Investigational New Drug Application for Treatment of Meniere's Disease
CUPERTINO, Calif., Jun 25, 2001 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it has filed a Special 510(k) pre-market notification with the FDA for its next generation ear delivery catheter. Like its predecessor IntraEAR(R) catheters, the Microdose Cath(TM) is intended for
Jun 25, 2001 DURECT Announces Filing of Special 510(k) Application for its New Generation IntraEAR(R) Ear Catheter Product and Approval of Physician Sponsored Investigational New Drug Application for Treatment ...
CUPERTINO, Calif., June 25 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it has filed a Special 510(k) pre-market notification with the FDA for its next generation ear delivery catheter. Like its predecessor IntraEAR(R) catheters, the Microdose Cath(TM) is intended for the
May 24, 2001 DURECT Completes Construction of Commercial Manufacturing Facility
CUPERTINO, Calif., May 24 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX - news) today announced that it has completed construction of a commercial manufacturing facility that is expected to meet DURECT's production needs for Phase III clinical batches, FDA registration batches and commercial
May 11, 2001 DURECT Corporation Completes the Clinical Portion of Phase II Clinical Trial for DUROS Sufentanil
CUPERTINO, Calif., May 11 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that the company has completed the clinical portion of its Phase II clinical trial for the company's lead product, DUROS sufentanil. The last patient visit was completed and data analysis and report writing
Apr 30, 2001 DURECT Corporation Reports First Quarter 2001 Financial Results
CUPERTINO, Calif., April 30 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended March 31, 2001. The company's net loss attributable to common stockholders for the three months ended March 31, 2001 was $4.9 million or 11 cents per share,
Apr 30, 2001 DURECT Corporation Announces Acquisition of Southern BioSystems, Inc
CUPERTINO, Calif., April 30 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it has acquired Southern BioSystems, Inc. ("SBS"), a privately held company located in Birmingham, Alabama. SBS develops, manufactures and sells biodegradable polymer and non-polymer drug delivery
Apr 24, 2001 DURECT Corporation Invites You to Join Its First Quarter 2001 Conference Call on the Web
CUPERTINO, Calif., April 24 /PRNewswire Interactive News Release/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) first quarter financial results press release, you are invited to listen to its conference call that will be broadcast live over the Internet on Monday, April 30th, 2001 at
Apr 03, 2001 Dennis M. Fisher, MD Named Vice President for Medical Affairs
CUPERTINO, Calif., April 3 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that Dennis M. Fisher, M.D. has been promoted to the position of Vice President for Medical Affairs. Dr. Fisher joined DURECT in June 2000 as Medical Director. Dr.
Mar 27, 2001 DURECT Corporation Announces Long-Term Drug Supply Agreement With Mallinckrodt
CUPERTINO, Calif., March 27 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it has a long-term supply agreement with Mallinckrodt, a global manufacturer and marketer of specialty medical products. Mallinckrodt will supply DURECT's clinical and commercial requirements for
Mar 09, 2001 DURECT Corporation Announces Completion of Patient Enrollment in Phase II Clinical Trial for DUROS Sufentanil
CUPERTINO, Calif., March 9 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that the company has completed patient enrollment of its Phase II clinical trial for the company's lead product, DUROS sufentanil. Over 50 patients at 10 clinical centers were enrolled in the trial more
Mar 01, 2001 Armand P. Neukermans Appointed to the Board of Directors of DURECT Corporation
CUPERTINO, Calif., March 1 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today the appointment of Armand P. Neukermans Ph.D. to its Board of Directors. Dr. Neukermans is currently Chief Technical Officer of the Xros division at Nortel Networks. Dr.
Mar 01, 2001 DURECT Corporation Invites You to View Its Salomon Smith Barney Specialty Pharmaceuticals Conference Investor Presentation
CUPERTINO, Calif., March 1 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present a company overview and discuss the Phase II trial in progress for its lead product, DUROS sufentanil for the treatment of chronic pain, at the 1st Annual Salomon Smith Barney Specialty
Feb 16, 2001 DURECT Corporation Announces Earnings and Reports Strong Progress on Its Business
CUPERTINO, Calif., Feb. 16 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months and year ended December 31, 2000 and reports strong progress in the company's business operations. The company reiterated its accelerated progress in the Phase II
Feb 15, 2001 DURECT Corporation Reports Fourth Quarter 2000 and Year End Financial Results
CUPERTINO, Calif., Feb. 15 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months and year ended December 31, 2000. The Company's net loss attributable to common stockholders for the three months ended December 31, 2000 was $4.9 million or 11 cents
Feb 07, 2001 DURECT Announces Acceleration of Completion of Patient Enrollment in its Phase II Clinical Trial for DUROS Sufentanil
CUPERTINO, Calif., Feb. 7 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that the company expects to complete enrollment of its 50 patient Phase II clinical trial for the company's lead product, DUROS sufentanil, ahead of the previously anticipated date for completion of
Jan 24, 2001 Evelyn R. Robledo Named Vice President of Quality Assurance and Compliance
CUPERTINO, Calif., Jan. 24 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that Evelyn R. Robledo has been promoted to Vice President of Quality Assurance and Compliance. Ms. Robledo joined DURECT in March 2000 and, utilizing her solid understanding of FDA regulations, developed
Jan 22, 2001 DURECT Corporation Invites You to Join its Fourth Quarter Conference Call on the Web
CUPERTINO, Calif., Jan. 22 /PRNewswire/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) fourth quarter financial results press release, you are invited to listen to its conference call that will be broadcast live over the Internet on Thursday, February 15, 2001 at 4:30 p.m.
Dec 12, 2000 DURECT Corporation Invites You to View Its Chase H&Q Healthcare Conference Investor Presentation
CUPERTINO, Calif., Dec. 12 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it will present a company overview and discuss the Phase II trial in progress for its lead product, DUROS sufentanil for the treatment of chronic pain, at the 19th Annual Healthcare Conference to be
Dec 11, 2000 DURECT Corporation Enrolls Patients in Phase II Clinical Trial for DUROS Sufentanil
CUPERTINO, Calif., Dec. 11 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced enrollment of the patients into a Phase II clinical trial for the company's lead product, DUROS sufentanil, for the treatment of chronic pain. DUROS sufentanil uses the DUROS osmotic delivery system to
Nov 13, 2000 DURECT Corporation Reports Third Quarter 2000 Financial Results
CUPERTINO, Calif., Nov. 13 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended September 30, 2000. DURECT's net loss attributable to common stockholders for its third quarter ended September 30, 2000 was $6.0 million dollars, or $0.62 cents
Nov 07, 2000 DURECT Corporation Invites You to Join Its Third Quarter Conference Call on the Web
CUPERTINO, Ca., Nov. 7 /PRNewswire/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) third quarter financial results press release, you are invited to listen to its conference call that will be broadcast live over the Internet on Monday, November 13, 2000 at 4:30 p.m.
Nov 02, 2000 DURECT Corporation Announces Exercise of Over-allotment Option in Initial Public Offering
CUPERTINO, Calif., Nov. 2 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that the underwriters of its recent initial public offering of common stock have exercised their over-allotment option in part and purchased an additional 700,000 shares at the initial public offering price
Oct 24, 2000 DURECT Corporation Announces Commencement of Construction of Commercial Manufacturing Facility in Cupertino, CA
CUPERTINO, Calif., Oct. 23 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it has commenced construction of a commercial manufacturing facility that is expected to meet DURECT's production needs for Phase III clinical trials currently planned for late 2001 and commercial
Sep 28, 2000 DURECT Announces Initial Public Offering
CUPERTINO, CA, September 28, 2000 – DURECT Corporation today announced the initial public offering of 7,000,000 shares of its Common Stock at a price to the public of $12 per share. Durect Corporation’s Common Stock will be listed on the NASDAQ National Market under the symbol “DRRX” and will begin
Apr 20, 2000 DURECT Announces Filing of Registration Statement
Cupertino, California - PRNewswire -- DURECT Corporation today announced that it has filed with the Securities Exchange Commission a registration statement relating to an initial public offering of its shares of common stock. All of the shares to be offered will be sold by the Company.
Oct 06, 1999 DURECT Corporation Acquires IntraEAR, Inc.
Pharmaceutical Firm Accelerates Activities in Ear Disorders Area Cupertino, California - PRNewswire -- DURECT Corporation, a pioneer in drug therapy treatments employing continuous drug delivery technology, today announced that it has acquired substantially all of the assets of IntraEAR, Inc.
Aug 12, 1999 Genetronics Announces Election of Dr. Felix Theeuwes, A Drug Delivery Pioneer, to Its Board of Directors
San Diego, California - PRNewswire -- Genetronics Biomedical Ltd. (Amex: GEB; Toronto) today announced it has elected Felix Theeuwes, D.Sc., as a new member of its Board of Directors. Dr. Theeuwes is Chairman and Chief Scientific Officer at DURECT Corporation, which was established in 1998 to focus
Aug 02, 1999 Pharmaceutical Firm Developing Therapies for Promising New Drug Delivery System
PRNewswire -- DURECT Corporation, a pioneer in drug therapy treatments employing subcutaneous delivery technology, today announced the closing of a $20 million private placement of preferred convertible stock. The Series B placement led by Brookside Capital, a Bain Capital Fund, is DURECT's second